in	O
the	O
cell	O
lines	O
.	O
Immunostaining	O
showed	O
no	O
LMP-1	O
,	O
EBNA-2	O
or	O
ZEBRA	B-protein
antigens	I-protein
in	O
the	O
paraffin-embedded	O
tissue	O
sections	O
,	O
although	O
they	O
were	O
positive	O
in	O
the	O
cell	O
line	O
cells	O
.	O
Latent	O
BHRF1	O
transcripts	O
encoding	O
bcl-2	O
homologue	O
and	O
BCRF1	O
transcripts	O
encoding	O
viral	O
interleukin	O
(	O
vIL	O
)	O
-10	O
were	O
detected	O
in	O
one	O
and	O
two	O
of	O
eight	O
patients	O
,	O
respectively	O
.	O
A	O
patient	O
with	O
NK-cell	O
lymphoma	O
expressing	O
both	O
transcripts	O
died	O
of	O
rapid	O
progression	O
of	O
the	O
illness	O
.	O
Our	O
results	O
indicate	O
that	O
the	O
restricted	O
expression	O
of	O
the	O
latency-associated	O
EBV	O
genes	O
and	O
the	O
production	O
of	O
vIL-10	O
and	O
bcl-2	O
homologue	O
may	O
favour	O
tumour	O
growth	O
,	O
evading	O
the	O
host	O
immune	O
surveillance	O
.	O
Copyright	O
2001	O
Cancer	O
Research	O
Campaign	O
.	O
Oxidized	O
alkyl	O
phospholipids	O
are	O
specific	O
,	O
high	B-protein
affinity	I-protein
peroxisome	I-protein
proliferator-activated	I-protein
receptor	I-protein
gamma	I-protein
ligands	I-protein
and	O
agonists	O
.	O
Synthetic	O
high	B-protein
affinity	I-protein
peroxisome	I-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
PPAR	O
)	O
agonists	O
are	O
known	O
,	O
but	O
biologic	O
ligands	O
are	O
of	O
low	O
affinity	O
.	O
Oxidized	O
low	O
density	O
lipoprotein	O
(	O
oxLDL	O
)	O
is	O
inflammatory	O
and	O
signals	O
through	O
PPARs	O
.	O
We	O
showed	O
,	O
by	O
phospholipase	B-protein
A	I-protein
(	I-protein
1	I-protein
)	O
digestion	O
,	O
that	O
PPARgamma	B-protein
agonists	O
in	O
oxLDL	O
arise	O
from	O
the	O
small	O
pool	O
of	O
alkyl	O
phosphatidylcholines	O
in	O
LDL	O
.	O
We	O
identified	O
an	O
abundant	O
oxidatively	O
fragmented	O
alkyl	O
phospholipid	O
in	O
oxLDL	O
,	O
hexadecyl	O
azelaoyl	O
phosphatidylcholine	O
(	O
azPC	O
)	O
,	O
as	O
a	O
high	B-protein
affinity	I-protein
ligand	I-protein
and	O
agonist	O
for	O
PPARgamma	B-protein
.	O
[	O
(	O
3	O
)	O
H	O
]	O
azPC	O
bound	O
recombinant	O
PPARgamma	B-protein
with	O
an	O
affinity	O
(	O
K	O
(	O
d	O
)	O
(	O
(	O
app	O
)	O
)	O
approximately	O
40	O
nm	O
)	O
that	O
was	O
equivalent	O
to	O
rosiglitazone	O
(	O
BRL49653	O
)	O
,	O
and	O
competition	O
with	O
rosiglitazone	O
showed	O
that	O
binding	O
occurred	O
in	O
the	O
ligand-binding	O
pocket	O
.	O
azPC	O
induced	O
PPRE	O
reporter	O
gene	O
expression	O
,	O
as	O
did	O
rosiglitazone	O
,	O
with	O
a	O
half-maximal	O
effect	O
at	O
100	O
nm	O
.	O
Overexpression	O
of	O
PPARalpha	O
or	O
PPARgamma	B-protein
revealed	O
that	O
azPC	O
was	O
a	O
specific	O
PPARgamma	B-protein
agonist	O
.	O
The	O
scavenger	B-protein
receptor	I-protein
CD36	I-protein
is	O
encoded	O
by	O
a	O
PPRE-responsive	O
gene	O
,	O
and	O
azPC	O
enhanced	O
expression	O
of	O
CD36	O
in	O
primary	O
human	O
monocytes	O
.	O
We	O
found	O
that	O
anti-CD36	O
inhibited	O
azPC	O
uptake	O
,	O
and	O
it	O
inhibited	O
PPRE	O
reporter	O
induction	O
.	O
Results	O
with	O
a	O
small	O
molecule	O
phospholipid	O
flippase	O
mimetic	O
suggest	O
azPC	O
acts	O
intracellularly	O
and	O
that	O
cellular	O
azPC	O
accumulation	O
was	O
efficient	O
.	O
Thus	O
,	O
certain	O
alkyl	O
phospholipid	O
oxidation	O
products	O
in	O
oxLDL	O
are	O
specific	O
,	O
high	O
affinity	O
extracellular	O
ligands	O
and	O
agonists	O
for	O
PPARgamma	B-protein
that	O
induce	O
PPAR-responsive	O
genes	O
Regulation	O
of	O
the	O
human	O
MAT2B	O
gene	O
encoding	O
the	O
regulatory	B-protein
beta	I-protein
subunit	I-protein
of	O
methionine	O
adenosyltransferase	O
,	O
MAT	B-protein
II	I-protein
.	O
Methionine	O
adenosyltransferase	O
(	O
MAT	O
)	O
catalyzes	O
the	O
biosynthesis	O
of	O
S-adenosylmethionine	O
(	O
AdoMet	O
)	O
,	O
a	O
key	O
molecule	O
in	O
transmethylation	O
reactions	O
and	O
polyamine	O
biosynthesis	O
.	O
The	O
MAT	O
II	O
isozyme	O
consists	O
of	O
a	O
catalytic	B-protein
alpha2	I-protein
and	I-protein
a	I-protein
regulatory	I-protein
beta	I-protein
subunit	I-protein
.	O
Down-regulation	O
of	O
the	O
MAT	B-protein
II	I-protein
beta	I-protein
subunit	I-protein
expression	O
causes	O
a	O
6-10-fold	O
increase	O
in	O
intracellular	O
AdoMet	O
levels	O
.	O
To	O
understand	O
the	O
mechanism	O
by	O
which	O
the	O
beta	O
subunit	O
expression	O
is	O
regulated	O
,	O
we	O
cloned	O
the	O
MAT2B	O
gene	O
,	O
determined	O
its	O
organization	O
,	O
characterized	O
its	O
5'-flanking	O
sequences	O
,	O
and	O
elucidated	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
regulation	O
of	O
its	O
promoter	O
.	O
Transcription	O
of	O
the	O
MAT2B	O
gene	O
initiates	O
at	O
position	O
-203	O
relative	O
to	O
the	O
translation	O
start	O
site	O
.	O
Promoter	O
deletion	O
analysis	O
defined	O
a	O
minimal	O
promoter	O
between	O
positions	O
+52	O
and	O
+93	O
base	O
pairs	O
,	O
a	O
GC-rich	O
region	O
.	O
Inclusion	O
of	O
the	O
sequences	O
between	O
-4	B-protein
and	O
+52	O
enhanced	O
promoter	O
activity	O
;	O
this	O
was	O
primarily	O
because	O
of	O
an	O
Sp1	O
recognition	O
site	O
at	O
+9/+15	O
.	O
The	O
inclusion	O
of	O
sequences	O
up	O
to	O
position	O
-115	O
provided	O
full	O
activity	O
;	O
this	O
was	O
attributed	O
to	O
a	O
TATA	O
at	O
-32	O
.	O
The	O
Sp1	O
site	O
at	O
position	O
+9	O
was	O
key	O
for	O
the	O
formation	O
of	O
protein.DNA	B-protein
complexes	I-protein
.	O
Mutation	O
of	O
both	O
the	O
Sp1	O
site	O
at	O
+9	O
and	O
the	O
TATA	O
at	O
-32	O
reduced	O
promoter	O
activity	O
to	O
its	O
minimal	O
level	O
.	O
Supershift	O
assays	O
showed	O
no	O
effect	O
of	O
the	O
anti-Sp1	B-protein
antibody	I-protein
on	O
complex	O
formation	O
,	O
whereas	O
the	O
anti-Sp3	B-protein
antibody	I-protein
had	O
a	O
strong	O
effect	O
on	O
protein.DNA	O
complex	O
formation	O
,	O
suggesting	O
that	O
Sp3	O
is	O
one	O
of	O
the	O
main	O
factors	O
binding	O
to	O
this	O
Sp1	O
site	O
.	O
Chromatin	O
immunoprecipitation	O
assays	O
supported	O
the	O
involvement	O
of	O
both	O
Sp1	O
and	O
Sp3	O
in	O
complexes	O
formed	O
on	O
the	O
MAT2B	O
promoter	O
.	O
The	O
data	O
show	O
that	O
the	O
5'-untranslated	O
sequences	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
MAT2B	O
gene	O
and	O
identifies	O
the	O
Sp1	O
site	O
at	O
+9	O
as	O
a	O
potential	O
target	O
for	O
modulating	O
MAT2B	O
expression	O
,	O
a	O
process	O
that	O
can	O
have	O
a	O
major	O
effect	O
on	O
intracellular	O
AdoMet	O
levels	O
.	O
Molecular	O
pathogenesis	O
of	O
influenza	O
A	O
virus	O
infection	O
and	O
virus-induced	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
.	O
Despite	O
vaccines	O
and	O
antiviral	O
substances	O
influenza	O
still	O
causes	O
significant	O
morbidity	O
and	O
mortality	O
world	O
wide	O
.	O
Better	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
of	O
influenza	O
virus	O
replication	O
,	O
pathogenesis	O
and	O
host	O
immune	O
responses	O
is	O
required	O
for	O
the	O
development	O
of	O
more	O
efficient	O
means	O
of	O
prevention	O
and	O
treatment	O
of	O
influenza	O
.	O
Influenza	O
A	O
virus	O
,	O
which	O
replicates	O
in	O
epithelial	O
cells	O
and	O
leukocytes	O
,	O
regulates	O
host	O
cell	O
transcriptional	O
and	O
translational	O
systems	O
and	O
activates	O
,	O
as	O
well	O
as	O
downregulates	O
apoptotic	O
pathways	O
.	O
Influenza	O
A	O
virus	O
infection	O
results	O
in	O
the	O
production	O
of	O
chemotactic	O
(	O
RANTES	B-protein
,	O
MIP-1	B-protein
alpha	I-protein
,	O
MCP-1	B-protein
,	O
MCP-3	O
,	O
and	O
IP-10	O
)	O
,	O
pro-inflammatory	O
(	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-18	B-protein
,	O
and	O
TNF-alpha	B-protein
)	O
,	O
and	O
antiviral	O
(	O
IFN-alpha/beta	B-protein
)	I-protein
cytokines	I-protein
.	O
Cytokine	O
gene	O
expression	O
is	O
associated	O
with	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
AP-1	B-protein
,	O
STAT	B-protein
and	O
IRF	B-protein
signal	I-protein
transducing	I-protein
molecules	I-protein
in	O
influenza	O
A	O
virus-infected	O
cells	O
.	O
In	O
addition	O
of	O
upregulating	O
cytokine	O
gene	O
expression	O
,	O
influenza	O
A	O
virus	O
infection	O
activates	O
caspase-1	B-protein
enzyme	I-protein
,	O
which	O
is	O
involved	O
in	O
the	O
proteolytic	O
processing	O
of	O
proIL-1	O
beta	O
and	O
proIL-18	O
into	O
their	O
biologically	O
active	O
forms	O
.	O
Influenza	O
A	O
virus-induced	O
IFN-alpha/beta	B-protein
is	O
essential	O
in	O
host	O
's	O
antiviral	O
defence	O
by	O
activating	O
the	O
expression	O
of	O
antiviral	O
Mx	O
,	O
PKR	O
and	O
oligoadenylate	O
synthetase	O
genes	O
.	O
IFN-alpha/beta	B-protein
also	O
prolongs	O
T	O
cell	O
survival	O
,	O
upregulates	O
IL-12	B-protein
and	O
IL-18	O
receptor	O
gene	O
expression	O
and	O
together	O
with	O
IL-18	B-protein
stimulates	O
NK	O
and	O
T	O
cell	O
IFN-gamma	O
production	O
and	O
the	O
development	O
of	O
Th1-type	O
immune	O
response	O
.	O
Comparison	O
of	O
hprt	O
and	O
lacI	O
mutant	O
frequency	O
with	O
DNA	O
adduct	O
formation	O
in	O
N-hydroxy-2-acetylaminofluorene-treated	O
Big	O
Blue	O
rats	O
.	O
N-Hydroxy-2-acetylaminofluorene	O
(	O
N-OH-AAF	O
)	O
is	O
the	O
proximate	O
carcinogenic	O
metabolite	O
of	O
the	O
powerful	O
rat	O
liver	O
carcinogen	O
2-acetylaminofluorene	O
.	O
In	O
this	O
study	O
,	O
transgenic	O
Big	O
Blue	O
(	O
R	O
)	O
rats	O
were	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
in	O
vivo	O
mutagenicity	O
and	O
DNA	O
adduct	O
formation	O
by	O
N-OH-AAF	O
in	O
the	O
target	O
liver	O
compared	O
with	O
that	O
in	O
nontarget	O
tissues	O
.	O
Male	O
rats	O
were	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
25	O
mg	O
N-OH-AAF/kg	O
body	O
weight	O
by	O
injection	O
at	O
4-day	O
intervals	O
,	O
and	O
groups	O
of	O
treated	O
and	O
control	O
rats	O
were	O
euthanized	O
up	O
to	O
10	O
weeks	O
after	O
beginning	O
the	O
dosing	O
.	O
Mutant	O
frequencies	O
were	O
measured	O
in	O
the	O
spleen	O
lymphocyte	O
hprt	O
gene	O
,	O
and	O
lacI	O
mutant	O
frequencies	O
were	O
determined	O
in	O
the	O
liver	O
and	O
spleen	O
lymphocytes	O
.	O
At	O
6	O
weeks	O
after	O
beginning	O
the	O
dosing	O
,	O
the	O
hprt	O
mutant	O
frequency	O
in	O
spleen	O
lymphocytes	O
from	O
the	O
four-dose	O
group	O
was	O
16.5	O
x	O
10	O
(	O
-6	O
)	O
compared	O
with	O
3.2	O
x	O
10	O
(	O
-6	O
)	O
in	O
control	O
animals	O
.	O
Also	O
at	O
6	O
weeks	O
,	O
rats	O
given	O
one	O
,	O
two	O
,	O
or	O
four	O
doses	O
of	O
N-OH-AAF	O
had	O
lacI	O
mutant	O
frequencies	O
in	O
the	O
liver	O
of	O
97.6	O
,	O
155.6	O
,	O
and	O
406.8	O
x	O
10	O
(	O
-6	O
)	O
,	O
respectively	O
,	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
25.7	O
x	O
10	O
(	O
-6	O
)	O
;	O
rats	O
given	O
four	O
doses	O
had	O
lacI	O
mutant	O
frequencies	O
in	O
spleen	O
lymphocytes	O
of	O
55.8	O
x	O
10	O
(	O
-6	O
)	O
compared	O
with	O
a	O
control	O
frequency	O
of	O
20.4	O
x	O
10	O
(	O
-6	O
)	O
.	O
Additional	O
rats	O
were	O
evaluated	O
for	O
DNA	O
adduct	O
formation	O
in	O
the	O
liver	O
,	O
spleen	O
lymphocytes	O
,	O
and	O
bone	O
marrow	O
by	O
(	O
32	O
)	O
P-postlabeling	O
.	O
Adduct	O
analysis	O
was	O
conducted	O
1	O
day	O
after	O
one	O
,	O
two	O
,	O
and	O
four	O
treatments	O
with	O
N-OH-AAF	O
,	O
5	O
days	O
after	O
one	O
treatment	O
,	O
and	O
9	O
days	O
after	O
two	O
treatments	O
.	O
N-	O
(	O
Deoxyguanosin-8-yl	O
)	O
-2-aminofluorene	O
was	O
the	O
major	O
DNA	O
adduct	O
identified	O
in	O
all	O
the	O
tissues	O
examined	O
.	O
Adduct	O
concentrations	O
increased	O
with	O
total	O
dose	O
to	O
maximum	O
values	O
in	O
samples	O
taken	O
1	O
day	O
after	O
two	O
doses	O
,	O
and	O
remained	O
essentially	O
the	O
same	O
after	O
four	O
doses	O
.	O
In	O
samples	O
taken	O
after	O
four	O
doses	O
,	O
adduct	O
levels	O
were	O
103	O
,	O
28	O
,	O
and	O
7	O
fmol/microg	O
of	O
DNA	O
in	O
liver	O
,	O
spleen	O
lymphocytes	O
,	O
and	O
bone	O
marrow	O
,	O
respectively	O
.	O
The	O
results	O
indicate	O
that	O
the	O
extent	O
of	O
both	O
DNA	O
adduct	O
formation	O
and	O
mutant	O
induction	O
correlates	O
with	O
the	O
organ	O
specificity	O
for	O
N-OH-AAF	O
carcinogenesis	O
in	O
the	O
rat	O
.	O
37	O
:	O
195-202	O
,	O
2001	O
.	O
Published	O
2001	O
Wiley-Liss	O
,	O
Inc	O
.	O
Expression	O
of	O
Mad1	O
in	O
T	O
cells	O
leads	O
to	O
reduced	O
thymic	O
cellularity	O
and	O
impaired	O
mitogen-induced	O
proliferation	O
.	O
To	O
investigate	O
Mad1	O
function	O
in	O
vivo	O
,	O
transgenic	O
mice	O
were	O
generated	O
that	O
express	O
a	O
Mad1	O
transgene	O
in	O
T	O
lineage	O
cells	O
under	O
the	O
control	O
of	O
the	O
proximal	O
lck	O
promoter	O
.	O
Thymus	O
size	O
in	O
lck-Mad1	O
transgenic	O
mice	O
is	O
drastically	O
reduced	O
although	O
representation	O
of	O
the	O
various	O
thymocyte	O
sub	O
populations	O
appears	O
normal	O
.	O
To	O
investigate	O
more	O
closely	O
any	O
effects	O
of	O
Mad1	O
expression	O
on	O
thymocytes	O
,	O
we	O
examined	O
thymic	O
selection	O
using	O
MHC	O
class	O
I-restricted	O
H-Y-TCR	O
transgenic	O
mice	O
.	O
Mad1	O
expression	O
in	O
vivo	O
reduces	O
the	O
efficiency	O
of	O
positive	O
selection	O
.	O
Furthermore	O
,	O
thymocytes	O
and	O
splenic	O
T	O
cells	O
from	O
lck-Mad1	O
transgenic	O
mice	O
display	O
a	O
profound	O
proliferative	O
defect	O
in	O
response	O
to	O
activation	O
with	O
either	O
PMA/Ionomycin	O
or	O
immobilized	B-protein
anti-CD3/CD28	I-protein
antibody	I-protein
.	O
This	O
proliferative	O
defect	O
is	O
not	O
reversed	O
by	O
addition	O
of	O
exogenous	B-protein
IL-2	I-protein
and	O
is	O
p53-independent	O
.	O
The	O
growth	O
inhibition	O
caused	O
by	O
Mad1	O
is	O
overcome	O
by	O
expression	O
of	O
active	O
c-Myc	O
.	O
Differential	O
requirement	O
for	O
the	O
transcription	B-protein
factor	I-protein
PU.1	I-protein
in	O
the	O
generation	O
of	O
natural	O
killer	O
cells	O
versus	O
B	O
and	O
T	O
cells	O
.	O
PU.1	O
is	O
a	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
the	O
development	O
of	O
various	O
lymphoid	O
and	O
myeloid	O
cell	O
lineages	O
,	O
but	O
its	O
role	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
development	O
is	O
not	O
known	O
.	O
The	O
study	O
shows	O
that	O
PU.1	B-protein
is	O
expressed	O
in	O
NK	O
cells	O
and	O
that	O
,	O
on	O
cell	O
transfer	O
into	O
alymphoid	O
Rag2/gammac	O
(	O
-/-	O
)	O
mice	O
,	O
hematopoietic	O
progenitors	O
of	O
PU.1	O
(	O
-/-	O
)	O
fetal	O
liver	O
cells	O
could	O
generate	O
functional	O
NK	O
cells	O
but	O
not	O
B	O
or	O
T	O
cells	O
.	O
Nevertheless	O
,	O
the	O
numbers	O
of	O
bone	O
marrow	O
NK	O
cell	O
precursors	O
and	O
splenic	O
mature	O
NK	O
cells	O
were	O
reduced	O
compared	O
to	O
controls	O
.	O
Moreover	O
,	O
PU.1	O
(	O
-/-	O
)	O
NK	O
cells	O
displayed	O
reduced	O
expression	O
of	O
the	O
receptors	O
for	O
stem	B-protein
cell	I-protein
factor	I-protein
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-7	I-protein
,	O
suggesting	O
a	O
nonredundant	O
role	O
for	O
PU.1	O
in	O
regulating	O
the	O
expression	O
of	O
these	O
cytokine	O
receptor	O
genes	O
during	O
NK	O
cell	O
development	O
.	O
PU.1	O
(	O
-/-	O
)	O
NK	O
cells	O
also	O
showed	O
defective	O
expression	O
of	O
inhibitory	O
and	O
activating	O
members	O
of	O
the	O
Ly49	B-protein
family	I-protein
and	O
failed	O
to	O
proliferate	O
in	O
response	O
to	O
IL-2	B-protein
and	O
IL-12	B-protein
.	O
Thus	O
,	O
despite	O
the	O
less	O
stringent	O
requirement	O
for	O
PU.1	O
in	O
NK	O
cell	O
development	O
compared	O
to	O
B	O
and	O
T	O
cells	O
,	O
PU.1	B-protein
regulates	O
NK	O
cell	O
differentiation	O
and	O
homeostasis	O
.	O
Benzene-extracted	O
components	O
are	O
important	O
for	O
the	O
major	O
activity	O
of	O
diesel	O
exhaust	O
particles	O
:	O
effect	O
on	O
interleukin-8	O
gene	O
expression	O
in	O
human	O
bronchial	O
epithelial	O
cells	O
.	O
Epidemiologic	O
and	O
experimental	O
studies	O
suggest	O
that	O
diesel	O
exhaust	O
particles	O
(	O
DEPs	O
)	O
may	O
be	O
related	O
to	O
increasing	O
respiratory	O
mortality	O
and	O
morbidity	O
.	O
We	O
have	O
shown	O
that	O
DEPs	O
augmented	O
the	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
by	O
human	O
airway	O
epithelial	O
cells	O
in	O
vitro	O
.	O
To	O
better	O
understand	O
the	O
mechanisms	O
of	O
their	O
proinflammatory	O
activities	O
,	O
we	O
studied	O
the	O
effects	O
of	O
several	O
components	O
extracted	O
from	O
DEPs	O
on	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-8	O
expression	O
in	O
human	O
bronchial	O
epithelial	O
cell	O
line	O
BEAS-2B	O
and	O
normal	O
human	O
airway	O
epithelial	O
cells	O
obtained	O
from	O
very	O
peripheral	O
airways	O
by	O
an	O
ultrathin	O
bronchoscope	O
.	O
We	O
used	O
several	O
agents	O
active	O
on	O
signal	O
transduction	O
pathways	O
in	O
cytokine	O
expression	O
,	O
such	O
as	O
the	O
protein	O
kinase	O
C	O
inhibitor	O
staurosporin	O
,	O
antioxidant	O
agents	O
including	O
N-acetyl	O
cysteine	O
(	O
NAC	O
)	O
and	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
and	O
p38	B-protein
mitogen-activated	I-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
inhibitor	O
SB203580	O
.	O
Benzene-extracted	O
components	O
showed	O
effects	O
mimicking	O
DEPs	O
on	O
IL-8	O
gene	O
expression	O
,	O
release	O
of	O
several	O
cytokines	B-protein
(	O
IL-8	B-protein
;	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
;	O
and	O
regulated	O
on	O
activation	O
,	O
normal	O
T	O
cells	O
expressed	O
and	O
secreted	O
)	O
and	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activation	O
.	O
We	O
also	O
found	O
that	O
NAC	O
,	O
PDTC	O
,	O
and	O
SB203580	B-protein
suppressed	O
the	O
activities	O
of	O
DEPs	O
and	O
their	O
benzene	O
extracts	O
,	O
suggesting	O
the	O
roles	O
of	O
oxidants-mediated	O
NF-kappa	O
B	O
activation	O
and	O
p38MAPK	O
pathways	O
.	O
Finally	O
,	O
benzo	O
[	O
a	O
]	O
pyrene	O
,	O
one	O
of	O
the	O
important	O
compounds	O
included	O
in	O
the	O
benzene	O
component	O
,	O
replicated	O
the	O
activities	O
shown	O
by	O
DEPs	O
.	O
The	O
nuclear	B-protein
receptor	I-protein
PPAR	I-protein
gamma	I-protein
is	O
expressed	O
by	O
mouse	O
T	O
lymphocytes	O
and	O
PPAR	B-protein
gamma	I-protein
agonists	O
induce	O
apoptosis	O
.	O
Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	I-protein
-gamma	I-protein
is	O
a	O
nuclear	B-protein
hormone	I-protein
receptor	I-protein
that	O
serves	O
as	O
a	O
trans	O
factor	O
to	O
regulate	O
lipid	O
metabolism	O
.	O
Intense	O
interest	O
is	O
focused	O
on	O
PPAR-gamma	O
and	O
its	O
ligands	O
owing	O
to	O
its	O
putative	O
role	O
in	O
adipocyte	O
differentiation	O
.	O
Little	O
is	O
known	O
,	O
however	O
,	O
about	O
the	O
functions	O
of	O
PPAR-gamma	B-protein
in	O
the	O
immune	O
system	O
,	O
especially	O
in	O
T	O
lymphocytes	O
.	O
We	O
demonstrate	O
that	O
both	O
naive	O
and	O
activated	O
ovalbumin-specific	O
T	O
cells	O
from	O
DO11.10-transgenic	O
mice	O
express	O
PPAR-gamma	O
mRNA	O
and	O
protein	O
.	O
In	O
order	O
to	O
determine	O
the	O
function	O
of	O
PPAR-gamma	B-protein
,	O
T	O
cells	O
were	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
or	O
antigen	B-protein
and	O
antigen-presenting	O
cells	O
.	O
Simultaneous	O
exposure	O
to	O
PPAR-gamma	B-protein
ligands	I-protein
(	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
-prostaglandin	O
J	O
(	O
2	O
)	O
,	O
troglitazone	O
)	O
showed	O
drastic	O
inhibition	O
of	O
proliferation	O
and	O
significant	O
decreases	O
in	O
cell	O
viability	O
.	O
The	O
decrease	O
in	O
cell	O
viability	O
was	O
due	O
to	O
apoptosis	O
of	O
the	O
T	O
lymphocytes	O
,	O
and	O
occurred	O
only	O
when	O
cells	O
were	O
treated	O
with	O
PPAR-gamma	O
,	O
and	O
not	O
PPAR-alpha	O
agonists	O
,	O
revealing	O
specificity	O
of	O
this	O
response	O
for	O
PPAR-gamma	O
.	O
These	O
observations	O
suggest	O
that	O
PPAR-gamma	O
agonists	O
play	O
an	O
important	O
role	O
in	O
regulating	O
T	O
cell-mediated	O
immune	O
responses	O
by	O
inducing	O
apoptosis	O
.	O
T	O
cell	O
death	O
via	O
PPAR-gamma	O
ligation	O
may	O
act	O
as	O
a	O
potent	O
anti-inflammatory	O
signal	O
in	O
the	O
immune	O
system	O
,	O
and	O
ligands	O
could	O
possibly	O
be	O
used	O
to	O
control	O
disorders	O
in	O
which	O
excessive	O
inflammation	O
occurs	O
.	O
Suppression	O
of	O
lung	O
inflammation	O
in	O
rats	O
by	O
prevention	O
of	O
NF-kappaB	B-protein
activation	O
in	O
the	O
liver	O
.	O
Activation	O
of	O
NF-kappaB	B-protein
and	O
production	O
of	O
NF-kappaB	B-protein
-dependent	O
chemokines	O
are	O
thought	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
neutrophilic	O
lung	O
inflammation	O
.	O
Calpain-1	O
inhibitor	O
(	O
CI-1	O
)	O
blocks	O
activation	O
of	O
NF-kappaB	B-protein
by	O
preventing	O
proteolysis	O
of	O
the	O
inhibitory	B-protein
protein	I-protein
IkappaB-alpha	B-protein
by	O
the	O
ubiquitin/proteasome	O
pathway	O
.	O
We	O
hypothesized	O
that	O
inhibition	O
of	O
proteasome	B-protein
function	O
with	O
CI-1	O
would	O
block	O
NF-kappaB	B-protein
activation	O
in	O
vivo	O
after	O
intraperitoneal	O
(	O
)	O
treatment	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
and	O
that	O
NF-kappaB	B-protein
inhibition	O
would	O
be	O
associated	O
with	O
suppression	O
of	O
chemokine	O
gene	O
expression	O
and	O
attenuation	O
of	O
neutrophilic	O
alveolitis	O
.	O
We	O
treated	O
rats	O
with	O
a	O
single	O
injection	O
of	O
CI-1	O
(	O
10	O
mg/kg	O
)	O
two	O
hours	O
prior	O
to	O
LPS	O
(	O
7	O
mg/kg	O
)	O
.	O
Treatment	O
with	O
Cl-1	O
prevented	O
degradation	O
of	O
IkappaB-alpha	B-protein
and	O
activation	O
of	O
NF-kappaB	B-protein
in	O
the	O
liver	O
in	O
response	O
to	O
LPS	O
;	O
however	O
,	O
Cl-1	O
treatment	O
had	O
no	O
detected	O
effect	O
on	O
NF-kappaB	B-protein
activation	O
in	O
lung	O
tissue	O
.	O
CI-1	O
treatment	O
prior	O
to	O
LPS	O
resulted	O
in	O
40	O
%	O
lower	O
MIP-2	B-protein
concentration	O
in	O
lung	O
lavage	O
fluid	O
compared	O
to	O
rats	O
treated	O
with	O
vehicle	O
prior	O
to	O
LPS	O
(	O
502	O
+/-	O
112	O
pg/ml	O
vs.	O
859	O
+/-144	O
pg/ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O
In	O
addition	O
,	O
CI-1	O
treatment	O
substantially	O
inhibited	O
LPS-induced	O
neutrophilic	O
alveolitis	O
(	O
2.7+	O
/-	O
1.2	O
x	O
10	O
(	O
5	O
)	O
vs.	O
43.7	O
+/-	O
12.2	O
x	O
10	O
(	O
5	O
)	O
lung	O
lavage	O
neutrophils	O
,	O
P	O
<	O
0.01	O
)	O
.	O
These	O
data	O
indicate	O
that	O
NF-kappaB	B-protein
inhibition	O
in	O
the	O
liver	O
can	O
alter	O
lung	O
inflammation	O
induced	O
by	O
systemic	O
LPS	O
treatment	O
and	O
suggest	O
that	O
a	O
liver-lung	O
interaction	O
contributes	O
to	O
the	O
inflammatory	O
response	O
of	O
the	O
lung	O
.	O
Notch1	O
regulates	O
maturation	O
of	O
CD4+	O
and	O
CD8+	O
thymocytes	O
by	O
modulating	O
TCR	O
signal	O
strength	O
.	O
Notch	O
signaling	O
regulates	O
cell	O
fate	O
decisions	O
in	O
multiple	O
lineages	O
.	O
We	O
demonstrate	O
in	O
this	O
report	O
that	O
retroviral	O
expression	O
of	O
activated	O
Notch1	O
in	O
mouse	O
thymocytes	O
abrogates	O
differentiation	O
of	O
immature	O
CD4+CD8+	O
thymocytes	O
into	O
both	O
CD4	O
and	O
CD8	O
mature	O
single-positive	O
T	O
cells	O
.	O
The	O
ability	O
of	O
Notch1	O
to	O
inhibit	O
T	O
cell	O
development	O
was	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
both	O
normal	O
and	O
TCR	B-protein
transgenic	O
thymocytes	O
.	O
Notch1	B-protein
-mediated	O
developmental	O
arrest	O
was	O
dose	O
dependent	O
and	O
was	O
associated	O
with	O
impaired	O
thymocyte	O
responses	O
to	O
TCR	B-protein
stimulation	O
.	O
Notch1	O
also	O
inhibited	O
TCR-mediated	O
signaling	O
in	O
Jurkat	O
T	O
cells	O
.	O
These	O
data	O
indicate	O
that	O
constitutively	O
active	O
Notch1	O
abrogates	O
CD4+	O
and	O
CD8+	O
maturation	O
by	O
interfering	O
with	O
TCR	O
signal	O
strength	O
and	O
provide	O
an	O
explanation	O
for	O
the	O
physiological	O
regulation	O
of	O
Notch	O
expression	O
during	O
thymocyte	O
development	O
.	O
Expression	O
of	O
SART3	B-protein
antigen	I-protein
and	O
induction	O
of	O
CTLs	B-protein
by	O
SART3-derived	O
peptides	O
in	O
breast	O
cancer	O
patients	O
.	O
We	O
recently	O
reported	O
the	O
SART3	O
tumour-rejection	O
antigen	O
as	O
possessing	O
tumour	O
epitopes	O
capable	O
of	O
inducing	O
HLA-class	O
I-restricted	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTLs	O
)	O
.	O
This	O
study	O
investigated	O
expression	O
of	O
the	O
SART3	B-protein
antigen	I-protein
in	O
breast	O
cancer	O
to	O
explore	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
breast	O
cancer	O
patients	O
.	O
The	O
SART3	B-protein
antigen	I-protein
was	O
detected	O
in	O
all	O
of	O
the	O
breast	O
cancer	O
cell	O
lines	O
tested	O
,	O
30	O
of	O
40	O
(	O
75	O
%	O
)	O
breast	O
cancer	O
tissue	O
samples	O
,	O
and	O
0	O
of	O
3	O
non-tumourous	O
breast	O
tissue	O
samples	O
.	O
SART3	O
derived	O
peptides	O
at	O
positions	O
109-118	O
and	O
315-323	O
induced	O
HLA-A24	O
restricted	O
CTLs	O
that	O
reacted	O
to	O
breast	O
cancer	O
cells	O
from	O
the	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
of	O
breast	O
cancer	O
patients	O
.	O
Therefore	O
,	O
the	O
SART3	B-protein
antigen	I-protein
and	O
its	O
peptides	O
could	O
be	O
an	O
appropriate	O
molecule	O
for	O
use	O
in	O
specific	O
immunotherapy	O
of	O
the	O
majority	O
of	O
HLA-A24-positive	O
breast	O
cancer	O
patients	O
Autostimulation	O
of	O
the	O
Epstein-Barr	O
virus	O
BRLF1	O
promoter	O
is	O
mediated	O
through	O
consensus	O
Sp1	O
and	O
Sp3	O
binding	O
sites	O
.	O
As	O
an	O
essential	O
step	O
in	O
the	O
lytic	O
cascade	O
,	O
the	O
Rta	O
homologues	O
of	O
gammaherpesviruses	O
all	O
activate	O
their	O
own	O
expression	O
.	O
Consistent	O
with	O
this	O
biologic	O
function	O
,	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
Rta	O
protein	O
powerfully	O
stimulates	O
the	O
promoter	O
of	O
its	O
own	O
gene	O
,	O
Rp	O
,	O
in	O
EBV-positive	O
B	O
cells	O
in	O
transient-transfection	O
reporter-based	O
assays	O
.	O
We	O
analyzed	O
the	O
activity	O
of	O
RpCAT	O
in	O
response	O
to	O
Rta	O
by	O
deletional	O
and	O
site-directed	O
mutagenesis	O
.	O
Two	O
cognate	O
Sp1	O
binding	O
sites	O
located	O
at	O
-279	O
and	O
-45	O
relative	O
to	O
the	O
transcriptional	O
start	O
site	O
proved	O
crucial	O
for	O
Rta-mediated	O
activation	O
.	O
Previously	O
described	O
binding	O
sites	O
for	O
the	O
cellular	B-protein
transcription	I-protein
factor	I-protein
Zif268	I-protein
and	O
the	O
viral	O
transactivator	O
ZEBRA	O
were	O
found	O
to	O
be	O
dispensable	O
for	O
activation	O
of	O
RpCAT	O
by	O
Rta	O
.	O
Gel	O
shift	O
analysis	O
,	O
using	O
extracts	O
of	O
B	O
cells	O
in	O
latency	O
or	O
induced	O
into	O
the	O
lytic	O
cycle	O
,	O
identified	O
Sp1	O
and	O
Sp3	O
as	O
the	O
predominant	B-protein
cellular	I-protein
proteins	I-protein
bound	O
to	O
Rp	O
near	O
-45	O
.	O
During	O
the	O
lytic	O
cycle	O
,	O
ZEBRA	B-protein
bound	O
Rp	O
near	O
the	O
Sp1/Sp3	O
site	O
.	O
The	O
binding	O
of	O
Sp1	B-protein
and	O
Sp3	O
to	O
Rp	O
correlated	O
with	O
the	O
reporter	O
activities	O
in	O
the	O
mutagenesis	O
study	O
,	O
establishing	O
a	O
direct	O
link	O
between	O
transcriptional	O
activation	O
of	O
Rp	O
by	O
Rta	O
and	O
DNA	O
binding	O
by	O
Sp1	O
and/or	O
Sp3	O
.	O
The	O
relative	O
abundance	O
or	O
functional	O
state	O
of	O
the	O
cellular	O
Sp1	O
and	O
Sp3	B-protein
transcription	I-protein
factors	I-protein
may	O
be	O
altered	O
in	O
response	O
to	O
stimuli	O
that	O
induce	O
the	O
BRLF1	O
promoter	O
and	O
thereby	O
contribute	O
to	O
the	O
activation	O
of	O
the	O
viral	O
lytic	O
cycle	O
.	O
Gene	O
transfer	O
of	O
antisense	B-protein
hypoxia	I-protein
inducible	I-protein
factor-1	I-protein
alpha	I-protein
enhances	O
the	O
therapeutic	O
efficacy	O
of	O
cancer	O
immunotherapy	O
.	O
Solid	O
tumors	O
meet	O
their	O
demands	O
for	O
nascent	O
blood	O
vessels	O
and	O
increased	O
glycolysis	O
,	O
to	O
combat	O
hypoxia	O
,	O
by	O
activating	O
multiple	O
genes	O
involved	O
in	O
angiogenesis	O
and	O
glucose	O
metabolism	O
.	O
Hypoxia	B-protein
inducible	I-protein
factor-1	I-protein
(	O
HIF-1	O
)	O
is	O
a	O
constitutively	O
expressed	O
basic	B-protein
helix-loop-helix	I-protein
transcription	I-protein
factor	I-protein
,	O
formed	O
by	O
the	O
assembly	O
of	O
HIF-1alpha	O
and	O
HIF-1beta	O
(	O
Arnt	O
)	O
,	O
that	O
is	O
stablized	O
in	O
response	O
to	O
hypoxia	O
,	O
and	O
rapidly	O
degraded	O
under	O
normoxic	O
conditions	O
.	O
It	O
activates	O
the	O
transcription	O
of	O
genes	O
important	O
for	O
maintaining	O
oxygen	O
homeostasis	O
.	O
Here	O
,	O
we	O
demonstrate	O
that	O
engineered	O
down-regulation	O
of	O
HIF-1alpha	O
by	O
intratumoral	O
gene	O
transfer	O
of	O
an	O
antisense	O
HIF-1alpha	O
plasmid	O
leads	O
to	O
the	O
down-regulation	O
of	O
VEGF	B-protein
,	O
and	O
decreased	O
tumor	O
microvessel	O
density	O
.	O
Antisense	O
HIF-1alpha	O
monotherapy	O
resulted	O
in	O
the	O
complete	O
and	O
permanent	O
rejection	O
of	O
small	O
(	O
0.1	O
cm	O
in	O
diameter	O
)	O
EL-4	O
tumors	O
,	O
which	O
is	O
unusual	O
for	O
an	O
anti-angiogenic	O
agent	O
where	O
transient	O
suppression	O
of	O
tumor	O
growth	O
is	O
the	O
norm	O
.	O
It	O
induced	O
NK	O
cell	O
-dependent	O
rejection	O
of	O
tumors	O
,	O
but	O
failed	O
to	O
stimulate	O
systemic	O
T	O
cell	O
-mediated	O
anti-tumor	O
immunity	O
,	O
and	O
synergized	O
with	O
B7-1-mediated	O
immunotherapy	O
to	O
cause	O
the	O
NK	O
cell	O
and	O
CD8	O
T	O
cell	O
-dependent	O
rejection	O
of	O
larger	O
EL-4	O
tumors	O
(	O
0.4	O
cm	O
in	O
diameter	O
)	O
that	O
were	O
refractory	O
to	O
monotherapies	O
.	O
Mice	O
cured	O
of	O
their	O
tumors	O
by	O
combination	O
therapy	O
resisted	O
a	O
rechallenge	O
with	O
parental	O
tumor	O
cells	O
,	O
indicating	O
systemic	O
antitumor	O
immunity	O
had	O
been	O
achieved	O
.	O
In	O
summary	O
,	O
whilst	O
intensive	O
investigations	O
are	O
in	O
progress	O
to	O
target	O
the	O
many	O
HIF-1	O
effectors	O
,	O
the	O
results	O
herein	O
indicate	O
that	O
blocking	O
hypoxia-inducible	O
pathways	O
and	O
enhancing	O
NK-mediated	O
antitumor	O
immunity	O
by	O
targeting	O
HIF-1	O
itself	O
may	O
be	O
advantageous	O
,	O
especially	O
when	O
combined	O
with	O
cancer	O
immunotherapy	O
.	O
Runx2	O
:	O
a	O
novel	O
oncogenic	O
effector	O
revealed	O
by	O
in	O
vivo	O
complementation	O
and	O
retroviral	O
tagging	O
.	O
The	O
Runx2	O
(	O
Cbfa1	O
,	O
Pebp2alphaA	O
,	O
Aml3	O
)	O
gene	O
was	O
previously	O
identified	O
as	O
a	O
frequent	O
target	O
for	O
transcriptional	O
activation	O
by	O
proviral	O
insertion	O
in	O
T-cell	O
lymphomas	O
of	O
CD2-MYC	O
transgenic	O
mice	O
.	O
We	O
have	O
recently	O
shown	O
that	O
over-expression	O
of	O
the	O
full-length	O
,	O
most	O
highly	O
expressed	O
Runx2	O
isoform	O
in	O
the	O
thymus	O
perturbs	O
T-cell	O
development	O
,	O
leads	O
to	O
development	O
of	O
spontaneous	O
lymphomas	O
at	O
low	O
frequency	O
and	O
is	O
strongly	O
synergistic	O
with	O
Myc	O
.	O
To	O
gain	O
further	O
insight	O
into	O
the	O
relationship	O
of	O
Runx2	O
to	O
other	O
lymphomagenic	O
pathways	O
,	O
we	O
tested	O
the	O
effect	O
of	O
combining	O
the	O
CD2-Runx2	O
transgene	O
either	O
with	O
a	O
Pim1	O
transgene	O
(	O
E	O
(	O
mu	O
)	O
-Pim1	O
)	O
or	O
with	O
the	O
p53	B-protein
null	O
genotype	O
,	O
as	O
each	O
of	O
these	O
displays	O
independent	O
synergy	O
with	O
Myc	O
.	O
In	O
both	O
cases	O
we	O
observed	O
synergistic	O
tumour	O
development	O
.	O
However	O
,	O
Runx2	O
appeared	O
to	O
have	O
a	O
dominant	O
effect	O
on	O
the	O
tumour	O
phenotype	O
in	O
each	O
case	O
,	O
with	O
most	O
tumours	O
conforming	O
to	O
the	O
CD3	B-protein
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
CD4	O
(	O
+/-	O
)	O
phenotype	O
seen	O
in	O
CD2-Runx2	O
mice	O
.	O
Neonatal	O
infection	O
of	O
CD2-Runx2	O
mice	O
with	O
Moloney	O
murine	O
leukaemia	O
virus	O
(	O
Moloney	O
MLV	O
)	O
also	O
led	O
to	O
a	O
dramatic	O
acceleration	O
of	O
tumour	O
onset	O
.	O
Analysis	O
of	O
known	O
Moloney	O
MLV	O
target	O
genes	O
in	O
these	O
lymphomas	O
showed	O
a	O
high	O
frequency	O
of	O
rearrangement	O
at	O
c-Myc	O
or	O
N-Myc	O
(	O
82	O
%	O
)	O
,	O
and	O
a	O
significant	O
number	O
at	O
Pim1	O
or	O
Pim2	O
(	O
23	O
%	O
)	O
,	O
and	O
at	O
Pal1/Gfi1	O
(	O
18	O
%	O
)	O
.	O
These	O
results	O
indicate	O
that	O
Runx2	O
makes	O
a	O
distinct	O
contribution	O
to	O
T-cell	O
lymphoma	O
development	O
which	O
does	O
not	O
coincide	O
with	O
any	O
of	O
the	O
oncogene	O
complementation	O
groups	O
previously	O
identified	O
by	O
retroviral	O
tagging	O
.	O
The	O
involvement	O
of	O
TNF-alpha	B-protein
-related	O
apoptosis-inducing	O
ligand	O
in	O
the	O
enhanced	O
cytotoxicity	O
of	O
IFN-beta	O
-stimulated	O
human	O
dendritic	O
cells	O
to	O
tumor	O
cells	O
.	O
TNF-alpha	B-protein
-related	I-protein
apoptosis-inducing	I-protein
ligand	I-protein
(	O
TRAIL	B-protein
)	O
is	O
characterized	O
by	O
its	O
preferential	O
induction	O
of	O
apoptosis	O
of	O
tumor	O
cells	O
but	O
not	O
normal	O
cells	O
.	O
Dendritic	O
cells	O
(	O
DCs	O
)	O
,	O
besides	O
their	O
role	O
as	O
APCs	O
,	O
now	O
have	O
been	O
demonstrated	O
to	O
exert	O
cytotoxicity	O
or	O
cytostasis	O
on	O
some	O
tumor	O
cells	O
.	O
Here	O
,	O
we	O
report	O
that	O
both	O
human	O
CD34	O
(	O
+	O
)	O
stem	O
cell	O
-derived	O
DCs	O
(	O
CD34DCs	O
)	O
and	O
human	B-protein
CD14	I-protein
(	O
+	O
)	O
monocyte	O
-derived	O
DCs	O
(	O
MoDCs	O
)	O
express	O
TRAIL	B-protein
and	O
exhibit	O
cytotoxicity	O
to	O
some	O
types	O
of	O
tumor	O
cells	O
partially	O
through	O
TRAIL	B-protein
.	O
Moderate	O
expression	O
of	O
TRAIL	B-protein
appeared	O
on	O
CD34DCs	O
from	O
the	O
8th	O
day	O
of	O
culture	O
and	O
was	O
also	O
seen	O
on	O
freshly	O
isolated	O
monocytes	O
.	O
The	O
level	O
of	O
TRAIL	B-protein
expression	O
remained	O
constant	O
until	O
DC	O
maturation	O
.	O
TRAIL	B-protein
expression	O
on	O
immature	O
CD34DCs	O
or	O
MoDCs	O
was	O
greatly	O
up-regulated	O
after	O
IFN-beta	O
stimulation	O
.	O
Moreover	O
,	O
IFN-beta	O
could	O
strikingly	O
enhance	O
the	O
ability	O
of	O
CD34DCs	O
or	O
MoDCs	O
to	O
kill	O
TRAIL-sensitive	O
tumor	O
cells	O
,	O
but	O
LPS	O
did	O
not	O
have	O
such	O
an	O
effect	O
.	O
The	O
up-regulation	O
of	O
TRAIL	B-protein
on	O
IFN-beta	B-protein
-stimulated	O
DCs	O
partially	O
contributed	O
to	O
the	O
increased	O
cytotoxicity	O
of	O
DCS	O
:	O
Pretreatment	O
of	O
TRAIL-sensitive	O
tumor	O
cells	O
with	O
caspase-3	O
inhibitor	O
could	O
significantly	O
increase	O
their	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
IFN-beta	B-protein
-stimulated	O
DCS	O
:	O
In	O
contrast	O
,	O
NF-kappaB	B-protein
inhibitor	O
could	O
significantly	O
increase	O
the	O
sensitivity	O
of	O
tumor	O
cells	O
to	O
the	O
killing	O
by	O
nonstimulated	O
or	O
LPS-stimulated	O
DCS	O
:	O
Our	O
studies	O
demonstrate	O
that	O
IFN-beta	B-protein
-stimulated	O
DCs	O
are	O
functionally	O
cytotoxic	O
.	O
Thus	O
,	O
an	O
innate	O
mechanism	O
of	O
DC-mediated	O
antitumor	O
immunity	O
might	O
exist	O
in	O
vivo	O
in	O
which	O
DCs	O
act	O
as	O
effectors	O
to	O
directly	O
kill	O
tumor	O
cells	O
partially	O
via	O
TRAIL	B-protein
.	O
Subsequently	O
,	O
DCs	O
act	O
as	O
APCs	O
involved	O
in	O
the	O
uptake	O
,	O
processing	O
,	O
and	O
presentation	O
of	O
apoptotic	O
tumor	O
Ags	O
to	O
cross-prime	O
CD8	O
(	O
+	O
)	O
CTL	O
cells	O
.	O
Tumor	O
cells	O
regulate	O
the	O
lytic	O
activity	O
of	O
tumor-specific	O
cytotoxic	O
t	O
lymphocytes	O
by	O
modulating	O
the	O
inhibitory	O
natural	O
killer	O
receptor	O
function	O
.	O
Tumor-infiltrating	O
p58+	O
T	O
cells	O
from	O
a	O
renal	O
tumor	O
were	O
specifically	O
expanded	O
in	O
response	O
to	O
tumor	O
cell	O
stimulation	O
and	O
cloned	O
.	O
These	O
p58+	O
T	O
cells	O
were	O
found	O
to	O
express	O
a	O
memory	O
phenotype	O
and	O
corresponded	O
to	O
clonal	O
TCRBV3	O
T-cell	O
expansion	O
.	O
Functionally	O
,	O
p58	O
(	O
+	O
)	O
CTLs	O
displayed	O
a	O
low	O
lytic	O
activity	O
for	O
HLA-A2	O
tumor	O
and	O
normal	O
cells	O
.	O
However	O
,	O
this	O
lytic	O
activity	O
was	O
significantly	O
increased	O
after	O
blockade	O
of	O
p58	O
with	O
specific	O
monoclonal	B-protein
antibodies	I-protein
.	O
Interestingly	O
,	O
we	O
demonstrated	O
that	O
stimulation	O
by	O
tumor	O
cells	O
was	O
required	O
to	O
trigger	O
the	O
inhibitory	O
effect	O
of	O
p58	O
on	O
the	O
lytic	O
activity	O
of	O
antigen-specific	O
CTLs	O
and	O
that	O
stimulation	O
of	O
the	O
inhibitory	O
function	O
of	O
p58	O
by	O
tumor	O
cells	O
correlated	O
with	O
an	O
inhibition	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
activation	O
in	O
p58+	O
tumor-specific	O
CTLS	O
.	O
T-cell	O
factor-1	O
expression	O
during	O
human	O
natural	O
killer	O
cell	O
development	O
and	O
in	O
circulating	O
CD56	O
(	O
+	O
)	O
bright	O
natural	O
killer	O
cells	O
.	O
Transcription	B-protein
factors	I-protein
are	O
essential	O
to	O
govern	O
differentiation	O
along	O
the	O
lymphoid	O
lineage	O
from	O
uncommitted	O
hematopoietic	O
stem	O
cells	O
.	O
Although	O
many	O
of	O
these	O
transcription	B-protein
factors	I-protein
have	O
putative	O
roles	O
based	O
on	O
murine	O
knockout	O
experiments	O
,	O
their	O
function	O
in	O
human	O
lymphoid	O
development	O
is	O
less	O
known	O
and	O
was	O
studied	O
further	O
.	O
Transcription	B-protein
factor	I-protein
expression	O
in	O
fresh	O
and	O
cultured	O
adult	O
human	O
bone	O
marrow	O
and	O
umbilical	O
cord	O
blood	O
progenitors	O
was	O
evaluated	O
.	O
We	O
found	O
that	O
fresh	O
CD34	O
(	O
+	O
)	O
Lin	O
(	O
-	O
)	O
cells	O
that	O
are	O
human	B-protein
leukocyte	I-protein
antigen	I-protein
(	O
HLA	O
)	O
-DR	O
(	O
-	O
)	O
or	O
CD38	O
(	O
-	O
)	O
constitutively	O
express	O
GATA-3	B-protein
but	O
not	O
T-cell	B-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
or	O
Id-3	O
.	O
Culture	O
with	O
the	O
murine	O
fetal	O
liver	O
cell	O
line	O
AFT024	O
and	O
defined	O
cytokines	B-protein
was	O
capable	O
of	O
inducing	O
TCF-1	O
mRNA	O
.	O
However	O
,	O
no	O
T-cell	O
receptor	O
gene	O
rearrangement	O
was	O
identified	O
in	O
cultured	O
progeny	O
.	O
Id-3	O
,	O
a	O
basic	O
helix	O
loop	O
helix	O
factor	O
with	O
dominant	O
negative	O
function	O
for	O
T-cell	O
differentiation	O
transcription	B-protein
factors	I-protein
,	O
also	O
was	O
upregulated	O
and	O
may	O
explain	O
unsuccessful	O
T-cell	O
maturation	O
.	O
To	O
better	O
understand	O
the	O
developmental	O
link	O
between	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
derived	O
from	O
progenitors	O
,	O
we	O
studied	O
NK	O
cell	O
subsets	O
circulating	O
in	O
blood	O
.	O
CD56	O
(	O
+bright	O
)	O
,	O
but	O
not	O
CD56	O
(	O
+dim	O
)	O
,	O
NK	O
cells	O
constitutively	O
express	O
TCF-1	B-protein
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blot	O
analysis	O
.	O
The	O
TCF-1	O
isoform	O
found	O
in	O
CD56	O
(	O
+bright	O
)	O
cells	O
,	O
which	O
express	O
lectin	B-protein
but	O
not	O
immunoglobulin	B-protein
class	I-protein
I	I-protein
recognizing	I-protein
inhibitory	I-protein
receptors	I-protein
,	O
was	O
identical	O
to	O
that	O
induced	O
in	O
NK	O
cell	O
differentiation	O
culture	O
and	O
was	O
distinctly	O
different	O
from	O
isoforms	O
in	O
T	O
cells	O
.	O
These	O
results	O
suggest	O
that	O
TCF-1	B-protein
does	O
not	O
target	O
human	O
killer	O
immunoglobulin	O
receptor	O
genes	O
,	O
TCF-1	B-protein
is	O
uniquely	O
expressed	O
in	O
circulating	O
CD56	O
(	O
+bright	O
)	O
NK	O
cells	O
,	O
and	O
specific	O
TCF-1	B-protein
isoforms	O
may	O
play	O
an	O
important	O
role	O
in	O
regulating	O
NK	O
differentiation	O
from	O
a	O
common	O
NK/T-cell	O
progenitor	O
.	O
Transcriptional	O
activation	O
by	O
a	O
matrix	B-protein
associating	I-protein
region-binding	I-protein
protein	I-protein
.	O
contextual	O
requirements	O
for	O
the	O
function	O
of	O
bright	O
.	O
Bright	O
(	O
B	O
cell	O
regulator	O
of	O
IgH	O
transcription	O
)	O
is	O
a	O
B	O
cell	O
-specific	O
,	O
matrix	B-protein
associating	I-protein
region-binding	I-protein
protein	I-protein
that	O
transactivates	O
gene	O
expression	O
from	O
the	O
IgH	O
intronic	O
enhancer	O
(	O
E	B-protein
mu	I-protein
)	O
.	O
We	O
show	O
here	O
that	O
Bright	O
has	O
multiple	O
contextual	O
requirements	O
to	O
function	O
as	O
a	O
transcriptional	B-protein
activator	I-protein
.	O
Bright	O
can	O
not	O
transactivate	O
via	O
out	O
of	O
context	O
,	O
concatenated	O
binding	O
sites	O
.	O
Transactivation	O
is	O
maximal	O
on	O
integrated	O
substrates	O
.	O
Two	O
of	O
the	O
three	O
previously	O
identified	O
binding	O
sites	O
in	O
E	O
mu	O
are	O
required	O
for	O
full	O
Bright	O
transactivation	O
.	O
The	O
Bright	B-protein
DNA	I-protein
binding	I-protein
domain	I-protein
defined	O
a	O
new	O
family	O
,	O
which	O
includes	O
SWI1	O
,	O
a	O
component	O
of	O
the	O
SWI.SNF	B-protein
complex	I-protein
shown	O
to	O
have	O
high	O
mobility	O
group-like	O
DNA	O
binding	O
characteristics	O
.	O
Similar	O
to	O
one	O
group	O
of	O
high	B-protein
mobility	I-protein
group	I-protein
box	I-protein
proteins	I-protein
,	O
Bright	O
distorts	O
E	O
mu	O
binding	O
site	O
-containing	O
DNA	O
on	O
binding	O
,	O
supporting	O
the	O
concept	O
that	O
it	O
mediates	O
E	O
mu	O
remodeling	O
.	O
Transfection	O
studies	O
further	O
implicate	O
Bright	O
in	O
facilitating	O
spatially	O
separated	O
promoter-enhancer	O
interactions	O
in	O
both	O
transient	O
and	O
stable	O
assays	O
.	O
Finally	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
Bright	B-protein
leads	O
to	O
enhanced	O
DNase	O
I	O
sensitivity	O
of	O
the	O
endogenous	B-protein
E	I-protein
mu	I-protein
matrix	I-protein
associating	I-protein
regions	I-protein
.	O
These	O
data	O
further	O
suggest	O
that	O
Bright	O
may	O
contribute	O
to	O
increased	O
gene	O
expression	O
by	O
remodeling	O
the	O
immunoglobulin	O
locus	O
during	O
B	O
cell	O
development	O
.	O
Analysis	O
of	O
BCL-6	O
mutations	O
in	O
classic	O
Hodgkin	O
disease	O
of	O
the	O
B-	O
and	O
T-cell	O
type	O
.	O
BCL-6	B-protein
is	O
essential	O
for	O
germinal	O
center	O
formation	O
and	O
thus	O
for	O
affinity	O
maturation	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
by	O
somatic	O
mutations	O
.	O
The	O
5'-noncoding	O
region	O
of	O
the	O
BCL-6	O
gene	O
is	O
even	O
a	O
target	O
for	O
the	O
mutation	O
machinery	O
.	O
Translocations	O
of	O
the	O
BCL-6	O
gene	O
to	O
heterologous	O
promoters	O
and	O
mutations	O
of	O
its	O
5'-noncoding	O
regulatory	O
region	O
were	O
reported	O
to	O
be	O
potential	O
mechanisms	O
for	O
deregulating	O
BCL-6	B-protein
expression	O
and	O
for	O
playing	O
a	O
role	O
in	O
the	O
genesis	O
of	O
non-Hodgkin	O
lymphoma	O
.	O
In	O
line	O
with	O
this	O
hypothesis	O
is	O
the	O
observation	O
that	O
B-cell	O
lymphoma	O
with	O
somatic	O
mutations	O
,	O
such	O
as	O
diffuse	O
large	O
B-cell	O
lymphoma	O
and	O
follicular	O
lymphoma	O
,	O
also	O
carry	O
BCL-6	O
mutations	O
,	O
some	O
of	O
which	O
are	O
recurrently	O
detectable	O
.	O
Classic	O
Hodgkin	O
disease	O
(	O
cHD	O
)	O
is	O
also	O
derived	O
from	O
B	O
cells	O
with	O
high	O
loads	O
of	O
somatic	O
mutations	O
and	O
thus	O
a	O
further	O
candidate	O
for	O
BCL-6	O
mutations	O
.	O
To	O
determine	O
the	O
presence	O
and	O
potential	O
role	O
of	O
BCL-6	O
mutations	O
in	O
cHD	O
,	O
the	O
5'-noncoding	O
BCL-6	O
proportion	O
of	O
single	O
Hodgkin	O
and	O
Reed-Sternberg	O
(	O
HRS	O
)	O
cells	O
from	O
6	O
cases	O
of	O
cHD	O
and	O
6	O
cases	O
of	O
HD-derived	O
cell	O
lines	O
was	O
analyzed	O
.	O
All	O
B-cell-derived	O
HD	O
cases	O
and	O
cell	O
lines	O
harbored	O
BCL-6	O
mutations	O
.	O
In	O
contrast	O
,	O
both	O
T-cell-derived	O
HD	O
cases	O
and	O
cell	O
lines	O
were	O
devoid	O
of	O
BCL-6	O
mutations	O
.	O
With	O
only	O
one	O
exception	O
,	O
there	O
were	O
no	O
lymphoma-specific	O
recurrent	O
BCL-6	O
mutations	O
detected	O
,	O
and	O
BCL-6	B-protein
protein	I-protein
was	O
absent	O
from	O
the	O
HRS	O
cells	O
of	O
most	O
cases	O
.	O
In	O
conclusion	O
,	O
(	O
1	O
)	O
somatic	O
BCL-6	O
mutations	O
are	O
restricted	O
to	O
cHD	O
cases	O
of	O
B-cell	O
origin	O
,	O
and	O
(	O
2	O
)	O
the	O
BCL-6	O
mutations	O
represent	O
mostly	O
irrelevant	O
somatic	O
base	O
substitutions	O
without	O
consequences	O
for	O
BCL-6	B-protein
protein	O
expression	O
and	O
the	O
pathogenesis	O
of	O
cHD	O
.	O
Gadd45gamma	O
is	O
dispensable	O
for	O
normal	O
mouse	O
development	O
and	O
T-cell	O
proliferation	O
.	O
Gadd45gamma	O
,	O
a	O
family	O
member	O
of	O
the	O
growth	O
arrest	O
and	O
DNA	O
damage-inducible	O
gene	O
family	O
45	O
(	O
Gadd45	O
)	O
,	O
is	O
strongly	O
induced	O
by	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
in	O
peripheral	O
T	O
cells	O
.	O
While	O
in	O
most	O
tissues	O
all	O
Gadd45	B-protein
family	I-protein
members	I-protein
are	O
expressed	O
,	O
Gadd45gamma	O
is	O
the	O
only	O
member	O
that	O
is	O
induced	O
by	O
IL-2	B-protein
.	O
Here	O
we	O
show	O
that	O
the	O
IL-2	B-protein
-induced	O
expression	O
of	O
Gadd45gamma	B-protein
is	O
dependent	O
on	O
a	O
signaling	O
pathway	O
mediated	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
Jak3	I-protein
and	O
the	O
transcription	B-protein
factors	I-protein
Stat5a	B-protein
and	O
Stat5b	B-protein
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
.	O
Previous	O
studies	O
with	O
ectopically	O
overexpressed	O
Gadd45gamma	O
in	O
various	O
cell	O
lines	O
implicated	O
its	O
function	O
in	O
negative	O
growth	O
control	O
.	O
To	O
analyze	O
the	O
physiological	O
role	O
of	O
Gadd45gamma	O
we	O
used	O
homologous	O
recombination	O
to	O
generate	O
mice	O
lacking	O
Gadd45gamma	O
.	O
Gadd45gamma	O
-deficient	O
mice	O
develop	O
normally	O
,	O
are	O
indistinguishable	O
from	O
their	O
littermates	O
,	O
and	O
are	O
fertile	O
.	O
Furthermore	O
,	O
hematopoiesis	O
in	O
mice	O
lacking	O
Gadd45gamma	O
is	O
not	O
impaired	O
and	O
Gadd45gamma	O
-deficient	O
T	O
lymphocytes	O
show	O
normal	O
responses	O
to	O
IL-2	B-protein
.	O
These	O
data	O
demonstrate	O
that	O
Gadd45gamma	O
is	O
not	O
essential	O
for	O
normal	O
mouse	O
development	O
and	O
hematopoiesis	O
,	O
possibly	O
due	O
to	O
functional	O
redundancy	O
among	O
the	O
Gadd45	B-protein
family	I-protein
members	I-protein
.	O
Gadd45gamma	O
is	O
also	O
dispensable	O
for	O
IL-2	B-protein
-induced	O
T-cell	O
proliferation	O
.	O
Decreased	O
expression	O
of	O
c-myc	O
family	O
genes	O
in	O
thymuses	O
from	O
myasthenia	O
gravis	O
patients	O
.	O
The	O
thymus	O
is	O
a	O
critical	O
organ	O
for	O
the	O
elimination	O
of	O
autoreactive	O
T	O
cells	O
by	O
apoptosis	O
.	O
We	O
studied	O
the	O
expression	O
of	O
apoptosis-associated	O
genes	O
,	O
bcl-xL	O
,	O
bad	O
,	O
caspase-3	B-protein
,	O
and	O
c-myc	O
family	O
genes	O
in	O
myasthenia	O
gravis	O
(	O
MG	O
)	O
thymuses	O
.	O
We	O
observed	O
that	O
the	O
mRNA	O
levels	O
of	O
myc	O
family	O
genes	O
,	O
c-myc	B-protein
and	O
max	O
,	O
were	O
markedly	O
reduced	O
in	O
MG	O
thymuses	O
.	O
These	O
results	O
indicate	O
that	O
c-myc	B-protein
-mediated	O
signaling	O
is	O
abnormal	O
in	O
MG	O
thymuses	O
.	O
The	O
levels	O
of	O
molecules	O
whose	O
expressions	O
are	O
associated	O
with	O
myc	O
,	O
such	O
as	O
STAM	O
,	O
prothymosin-alpha	O
,	O
and	O
NFkappaB	O
Immunohistochemical	O
detection	O
of	O
interferon-gamma-producing	O
cells	O
in	O
dermatophytosis	O
.	O
Skin	O
lesions	O
of	O
dermatophytosis	O
are	O
thought	O
to	O
be	O
a	O
result	O
of	O
a	O
T	O
cell	O
-dependent	O
inflammatory	O
response	O
that	O
is	O
mediated	O
by	O
various	O
cytokines	B-protein
.	O
We	O
examined	O
whether	O
IFN-gamma-positive	O
cells	O
(	O
as	O
expression	O
of	O
Th1	O
response	O
)	O
were	O
present	O
in	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	O
in	O
situ	O
by	O
immunohistochemical	O
techniques	O
.	O
Mixtures	O
of	O
CD4-positive	O
T	O
cells	O
and	O
CD8-positive	O
T	O
cells	O
were	O
found	O
to	O
be	O
present	O
in	O
the	O
dermal	O
infiltrates	O
of	O
the	O
lesions	O
.	O
Considerable	O
numbers	O
of	O
CD1a-positive	O
cells	O
were	O
detected	O
in	O
the	O
upper	O
dermis	O
and	O
epidermis	O
.	O
A	O
marked	O
accumulation	O
of	O
CD68-positive	O
cells	O
was	O
found	O
in	O
the	O
upper	O
dermis	O
.	O
IFN-gamma-positive	O
cells	O
were	O
present	O
in	O
the	O
upper	O
dermis	O
of	O
the	O
lesions	O
.	O
The	O
pattern	O
of	O
IFN-gamma	B-protein
staining	O
appeared	O
to	O
be	O
intracellular	O
in	O
mononuclear	O
lymphoid	O
cells	O
.	O
The	O
staining	O
was	O
considered	O
to	O
be	O
highly	O
specific	O
because	O
it	O
could	O
be	O
completely	O
blocked	O
by	O
preabsorption	O
with	O
recombinant	O
IFN-gamma	B-protein
.	O
Our	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
skin	O
lesions	O
of	O
dermatophytosis	O
may	O
be	O
associated	O
with	O
a	O
Th1	O
response	O
.	O
Th1	O
response	O
,	O
which	O
is	O
characterized	O
by	O
IFN-gamma	B-protein
release	O
,	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
host	O
defense	O
against	O
dermatophytes	O
and	O
to	O
reflect	O
cutaneous	O
reaction	O
in	O
dermatophytosis	O
.	O
Regulation	O
of	O
the	O
helix-loop-helix	B-protein
proteins	I-protein
,	O
E2A	B-protein
and	O
Id3	O
,	O
by	O
the	O
Ras	O
-	O
ERK	B-protein
MAPK	I-protein
cascade	O
.	O
Activation	O
of	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
pathways	O
leads	O
to	O
cellular	O
differentiation	O
and/or	O
proliferation	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
,	O
including	O
developing	O
thymocytes	O
.	O
The	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
proteins	I-protein
E12	B-protein
and	O
E47	B-protein
and	O
an	O
inhibitor	O
HLH	O
protein	O
,	O
Id3	O
,	O
play	O
key	O
roles	O
in	O
thymocyte	O
differentiation	O
.	O
We	O
show	O
here	O
that	O
E2A	O
DNA	O
binding	O
is	O
lowered	O
in	O
primary	O
immature	O
thymocytes	O
consequent	O
to	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
-mediated	O
ligation	O
.	O
Whereas	O
expression	O
of	O
E2A	O
mRNA	O
and	O
protein	O
are	O
unaltered	O
,	O
Id3	O
transcripts	O
are	O
rapidly	O
induced	O
upon	O
signaling	O
from	O
the	O
TCR	B-protein
.	O
Activation	O
of	O
Id3	O
transcription	O
is	O
regulated	O
in	O
a	O
dose-dependent	O
manner	O
by	O
the	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
(	O
ERK	B-protein
)	O
MAPK	O
module	O
.	O
These	O
observations	O
directly	O
connect	O
the	O
ERK	B-protein
MAPK	I-protein
cascade	I-protein
and	I-protein
HLH	I-protein
proteins	I-protein
in	O
a	O
linear	O
pathway	O
.	O
Retinoic	O
acid	O
up-regulates	O
myeloid	O
ICAM-3	O
expression	O
and	O
function	O
in	O
a	O
cell-specific	O
fashion	O
--	O
evidence	O
for	O
retinoid	O
signaling	O
pathways	O
in	O
the	O
mast	O
cell	O
lineage	O
.	O
Investigation	O
of	O
mast	O
cell	O
responsiveness	O
toward	O
retinoic	O
acid	O
(	O
RA	O
)	O
revealed	O
selective	O
promotion	O
of	O
ICAM-3	O
expression	O
in	O
the	O
human	O
mast	O
cell	O
line	O
HMC-1	O
.	O
This	O
process	O
was	O
dose-	O
and	O
time-dependent	O
and	O
detectable	O
by	O
flow	O
cytometry	O
,	O
Western	O
blot	O
analysis	O
,	O
ELISA	O
,	O
and	O
Northern	O
blot	O
analysis	O
.	O
ICAM-3	O
modulation	O
was	O
found	O
to	O
be	O
cell-type	O
dependent	O
,	O
detectable	O
also	O
for	O
HL-60	O
cells	O
and	O
monocytes	O
but	O
not	O
U-937	O
and	O
only	O
weakly	O
for	O
KU812	O
cells	O
.	O
Terminally	O
differentiated	O
skin	O
mast	O
cells	O
also	O
failed	O
to	O
up-modulate	O
their	O
ICAM-3	O
,	O
suggesting	O
the	O
requirement	O
for	O
some	O
degree	O
of	O
immaturity	O
for	O
the	O
process	O
.	O
RA-mediated	O
effects	O
on	O
ICAM-1	B-protein
expression	O
,	O
studied	O
in	O
parallel	O
,	O
were	O
clearly	O
distinct	O
from	O
those	O
on	O
ICAM-3	O
.	O
Investigation	O
of	O
retinoid	B-protein
receptor	I-protein
expression	O
,	O
known	O
to	O
mediate	O
intracellular	O
RA	O
signaling	O
,	O
revealed	O
presence	O
of	O
RAR	B-protein
alpha	I-protein
,	I-protein
RAR	I-protein
gamma	I-protein
,	O
RXR	B-protein
beta	I-protein
,	O
and	O
RXR	B-protein
gamma	I-protein
transcripts	I-protein
in	O
all	O
cell	O
lines	O
studied	O
,	O
and	O
HMC-1	O
cells	O
were	O
the	O
only	O
line	O
lacking	O
RXR	B-protein
alpha	I-protein
.	O
RAR	O
beta	O
,	O
not	O
expressed	O
at	O
baseline	O
,	O
was	O
induced	O
by	O
RA	O
in	O
a	O
fashion	O
obviously	O
correlating	O
with	O
ICAM-3	O
up-regulation	O
.	O
Increased	O
ICAM-3	O
expression	O
was	O
of	O
functional	O
significance	O
,	O
such	O
that	O
processes	O
stimulated	O
or	O
co-stimulated	O
via	O
ICAM-3	O
(	O
homotypic	O
aggregation	O
,	O
IL-8	O
secretion	O
)	O
were	O
clearly	O
enhanced	O
upon	O
RA	O
pretreatment	O
,	O
suggesting	O
that	O
RA	O
may	O
contribute	O
via	O
hitherto	O
unrecognized	O
pathways	O
to	O
immune	O
function	O
and	O
host	O
defense	O
.	O
CD28	B-protein
and	O
T	O
cell	O
co-stimulation	O
.	O
Over	O
the	O
last	O
decade	O
the	O
concept	O
of	O
T	O
cell	O
co-stimulation	O
has	O
emerged	O
to	O
take	O
a	O
central	O
role	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
.	O
However	O
,	O
the	O
exact	O
definition	O
of	O
co-stimulation	O
is	O
still	O
unclear	O
.	O
In	O
this	O
review	O
,	O
we	O
re-examine	O
the	O
concept	O
of	O
co-stimulation	O
.	O
We	O
suggest	O
that	O
while	O
co-stimulation	O
is	O
important	O
,	O
there	O
is	O
little	O
evidence	O
to	O
link	O
co-stimulation	O
with	O
T	O
cell	O
anergy	O
.	O
We	O
then	O
suggest	O
a	O
framework	O
for	O
studying	O
co-stimulation	O
.	O
Focusing	O
on	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
CD28	B-protein
,	O
we	O
discuss	O
four	O
areas	O
of	O
T	O
cell	O
activation	O
where	O
co-stimulation	O
may	O
play	O
a	O
role	O
.	O
Regulation	O
of	O
activator	B-protein
protein-1	I-protein
and	O
NF-kappa	B-protein
B	I-protein
in	O
CD8+	O
T	O
cells	O
exposed	O
to	O
peripheral	O
self-antigens	O
.	O
The	O
transcriptional	O
events	O
that	O
control	O
T	O
cell	O
tolerance	O
to	O
peripheral	O
self	O
Ags	O
are	O
still	O
unknown	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
regulation	O
of	O
AP-1	B-protein
-	O
and	O
NF-kappa	B-protein
B	I-protein
-mediated	O
transcription	O
during	O
in	O
vivo	O
induction	O
of	O
tolerance	O
to	O
a	O
self	O
Ag	O
expressed	O
exclusively	O
on	O
hepatocytes	O
.	O
Naive	O
CD8	O
(	O
+	O
)	O
Desire	O
(	O
Des	O
)	O
(	O
+	O
)	O
T	O
cells	O
isolated	O
from	O
the	O
Des	O
TCR-transgenic	O
mice	O
that	O
are	O
specific	O
for	O
the	O
H-2K	B-protein
(	I-protein
b	I-protein
)	I-protein
class	I-protein
I	I-protein
Ag	I-protein
were	O
transferred	O
into	O
Alb-K	O
(	O
b	O
)	O
-transgenic	O
mice	O
that	O
express	O
the	O
H-2K	O
(	O
b	O
)	O
Ag	O
on	O
hepatocytes	O
only	O
.	O
Tolerance	O
develops	O
in	O
these	O
mice	O
.	O
We	O
found	O
that	O
the	O
self-reactive	O
CD8	O
(	O
+	O
)	O
Des	O
(	O
+	O
)	O
T	O
cells	O
were	O
transiently	O
activated	O
,	O
then	O
became	O
unresponsive	O
and	O
were	O
further	O
deleted	O
.	O
In	O
contrast	O
to	O
CD8	O
(	O
+	O
)	O
Des	O
(	O
+	O
)	O
T	O
cells	O
activated	O
in	O
vivo	O
with	O
APCs	O
,	O
which	O
express	O
high	O
AP-1	B-protein
and	O
high	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	O
,	O
the	O
unresponsive	O
CD8	O
(	O
+	O
)	O
Des	O
(	O
+	O
)	O
T	O
cells	O
expressed	O
no	O
AP-1	B-protein
and	O
only	O
weak	O
NF-kappa	O
B	O
transcriptional	O
activity	O
.	O
The	O
differences	O
in	O
NF-kappa	O
B	O
transcriptional	O
activity	O
correlated	O
with	O
the	O
generation	O
of	O
distinct	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
.	O
Indeed	O
,	O
in	O
vivo	O
primed	O
T	O
cells	O
predominantly	O
express	O
p50/p50	O
and	O
p65/p50	B-protein
dimers	I-protein
,	O
whereas	O
these	O
p50-containing	B-protein
complexes	I-protein
are	O
barely	O
detectable	O
in	O
tolerant	O
T	O
cells	O
that	O
express	O
p65-	O
and	O
c-Rel-containing	B-protein
complexes	I-protein
.	O
These	O
observations	O
suggest	O
that	O
fine	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
formation	O
may	O
determine	O
T	O
cell	O
fate	O
.	O
Transcriptional	O
regulation	O
in	O
lymphocytes	O
.	O
Lymphocytes	O
have	O
been	O
used	O
to	O
investigate	O
many	O
cellular	O
processes	O
,	O
including	O
lineage	O
commitment	O
,	O
differentiation	O
,	O
proliferation	O
and	O
apoptosis	O
.	O
The	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
these	O
processes	O
are	O
often	O
expressed	O
broadly	O
in	O
many	O
cell	O
types	O
.	O
The	O
emerging	O
theme	O
is	O
one	O
of	O
cell-type-specific	O
regulation	O
,	O
affecting	O
not	O
only	O
the	O
functional	O
activation	O
of	O
transcription	B-protein
factors	I-protein
but	O
also	O
their	O
access	O
to	O
appropriate	O
regions	O
of	O
DNA	O
.	O
Existence	O
of	O
retinoic	O
acid-receptor	O
-independent	O
retinoid	O
X-receptor	O
-dependent	O
pathway	O
in	O
myeloid	O
cell	O
function	O
.	O
We	O
previously	O
reported	O
that	O
ER-27191	O
(	O
4-	O
[	O
4	O
,	O
5	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10-hexahydro-7	O
,	O
7	O
,	O
10	O
,	O
10-tetramethyl-1-	O
(	O
3-pyridylmethyl	O
)	O
anthra	O
[	O
1	O
,	O
2-b	O
]	O
pyrrol-3-yl	O
]	O
benzoic	O
acid	O
)	O
is	O
a	O
potent	O
antagonist	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	O
)	O
,	O
and	O
ER-35795	O
(	O
(	O
2E	O
,	O
4E	O
,	O
6E	O
)	O
-7-	O
[	O
1-	O
(	O
1-methylethyl	O
)	O
-8-chloro-1	O
,	O
2	O
,	O
3	O
,	O
4-tetrahydroquinolin-6-yl	O
]	O
-6-fluoro-3-methyl-2	O
,	O
4	O
,	O
6-nonatrienoic	O
acid	O
)	O
is	O
a	O
novel	O
retinoid	O
X	O
receptor	O
(	O
RXR	B-protein
)	I-protein
-specific	O
agonist	O
.	O
By	O
using	O
these	O
compounds	O
,	O
we	O
investigated	O
whether	O
distinct	O
RAR	O
-dependent	O
and	O
RXR	B-protein
-dependent	O
pathways	O
operate	O
to	O
mediate	O
the	O
diverse	O
activities	O
of	O
retinoids	O
,	O
particularly	O
,	O
the	O
effects	O
of	O
the	O
RXR	O
pathway	O
on	O
cellular	O
function	O
.	O
ER-27191	O
completely	O
antagonized	O
HL60	O
cell	O
differentiation	O
induced	O
by	O
all-trans-retinoic	O
acid	O
(	O
atRA	O
)	O
.	O
However	O
,	O
the	O
differentiation	O
induced	O
by	O
the	O
ER-35795	O
was	O
not	O
antagonized	O
at	O
all	O
by	O
the	O
RAR	O
antagonist	O
,	O
but	O
was	O
inhibited	O
by	O
an	O
RXR	O
homodimer	O
antagonist	O
(	O
LGD100754	O
,	O
(	O
2E	O
,	O
4E	O
,	O
6Z	O
)	O
-7-	O
(	O
3-n-propoxy-5	O
,	O
6	O
,	O
7	O
,	O
8-tetrahydro-5	O
,	O
5	O
,	O
8	O
,	O
8-tetramethylnaphthalen-2-yl	O
)	O
-3-methylocta-2	O
,	O
4	O
,	O
6-trienoic	O
acid	O
)	O
.	O
Its	O
agonistic	O
action	O
on	O
RXR/RAR	B-protein
heterodimer	I-protein
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
neutralized	O
by	O
the	O
RAR	O
antagonist	O
.	O
During	O
HL60	O
cell	O
differentiation	O
,	O
atRA	O
induced	O
RARbeta	O
mRNA	O
,	O
while	O
the	O
RXR	O
had	O
no	O
effect	O
.	O
Interestingly	O
,	O
a	O
functional	O
RXR	O
-pathway	O
was	O
also	O
seen	O
in	O
lipopolysaccharide-induced	O
inhibition	O
of	O
mouse	O
splenocyte	O
proliferation	O
.	O
These	O
results	O
strongly	O
suggest	O
the	O
existence	O
of	O
a	O
pharmacological	O
RXR	B-protein
-dependent	O
pathway	O
that	O
is	O
activated	O
by	O
a	O
ligand	O
that	O
can	O
bind	O
to	O
RXR	O
.	O
Targeting	O
Src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
SHP-1	O
)	O
into	O
lipid	O
rafts	O
inhibits	O
CD3	B-protein
-induced	O
T	O
cell	O
activation	O
.	O
To	O
study	O
the	O
mechanism	O
by	O
which	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPs	O
)	O
regulate	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	O
,	O
we	O
investigated	O
the	O
distribution	O
of	O
PTPs	O
in	O
subdomains	O
of	O
plasma	O
membrane	O
.	O
We	O
report	O
here	O
that	O
the	O
bulk	O
PTP	O
activity	O
associated	O
with	O
T	O
cell	O
membrane	O
is	O
present	O
outside	O
the	O
lipid	O
rafts	O
,	O
as	O
determined	O
by	O
sucrose	O
density	O
gradient	O
sedimentation	O
.	O
In	O
Jurkat	O
T	O
cells	O
,	O
approximately	O
5	O
--	O
10	O
%	O
of	O
Src	B-protein
homology	I-protein
2	I-protein
domain-containing	I-protein
tyrosine	I-protein
phosphatase	I-protein
(	O
SHP-1	O
)	O
is	O
constitutively	O
associated	O
with	O
plasma	O
membrane	O
,	O
and	O
nearly	O
50	O
%	O
of	O
SHP-2	B-protein
is	O
translocated	O
to	O
plasma	O
membrane	O
after	O
vanadate	O
treatment	O
.	O
Similar	O
to	O
transmembrane	O
PTP	O
,	O
CD45	O
,	O
the	O
membrane-associated	O
populations	O
of	O
SHP-1	B-protein
and	O
SHP-2	B-protein
are	O
essentially	O
excluded	O
from	O
lipid	O
rafts	O
,	O
where	O
other	O
signaling	O
molecules	O
such	O
as	O
Lck	B-protein
,	O
linker	O
for	O
activation	O
of	O
T	O
cells	O
,	O
and	O
CD3	O
zeta	O
are	O
enriched	O
.	O
We	O
further	O
demonstrated	O
that	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
these	O
substrates	O
is	O
largely	O
restricted	O
to	O
lipid	O
rafts	O
,	O
unless	O
PTPs	O
are	O
inhibited	O
.	O
It	O
suggests	O
that	O
a	O
restricted	O
partition	O
of	O
PTPs	O
among	O
membrane	O
subdomains	O
may	O
regulate	O
protein	O
tyrosine	O
phosphorylation	O
in	O
T	O
cell	O
membrane	O
.	O
To	O
test	O
this	O
hypothesis	O
,	O
we	O
targeted	O
SHP-1	O
into	O
lipid	O
rafts	O
by	O
using	O
the	O
N-terminal	O
region	O
of	O
Lck	B-protein
(	I-protein
residues	I-protein
1	I-protein
--	I-protein
14	I-protein
)	O
.	O
The	O
results	O
indicate	O
that	O
the	O
expression	O
of	O
Lck/SHP-1	O
chimera	O
inside	O
lipid	O
rafts	O
profoundly	O
inhibits	O
CD3	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
CD3	O
zeta/epsilon	O
,	O
IL-2	O
generation	O
,	O
and	O
nuclear	O
mobilization	O
of	O
NF-AT	B-protein
.	O
Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
exclusion	O
of	O
PTPs	O
from	O
lipid	O
rafts	O
may	O
be	O
a	O
mechanism	O
that	O
potentiates	O
TCR	B-protein
/	O
CD3	B-protein
activation	O
An	O
instructive	O
component	O
in	O
T	O
helper	O
cell	O
type	O
2	O
(	O
Th2	O
)	O
development	O
mediated	O
by	O
GATA-3	B-protein
.	O
Although	O
interleukin	O
(	O
IL	O
)	O
-12	O
and	O
IL-4	B-protein
polarize	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
toward	O
T	O
helper	O
cell	O
type	O
1	O
(	O
Th1	O
)	O
or	O
Th2	O
phenotypes	O
,	O
it	O
is	O
not	O
known	O
whether	O
cytokines	B-protein
instruct	O
the	O
developmental	O
fate	O
in	O
uncommitted	O
progenitors	O
or	O
select	O
for	O
outgrowth	O
of	O
cells	O
that	O
have	O
stochastically	O
committed	O
to	O
a	O
particular	O
fate	O
.	O
To	O
distinguish	O
these	O
instructive	O
and	O
selective	O
models	O
,	O
we	O
used	O
surface	O
affinity	O
matrix	O
technology	O
to	O
isolate	O
committed	O
progenitors	O
based	O
on	O
cytokine	O
secretion	O
phenotype	O
and	O
developed	O
retroviral-based	O
tagging	O
approaches	O
to	O
directly	O
monitor	O
individual	O
progenitor	O
fate	O
decisions	O
at	O
the	O
clonal	O
and	O
population	O
levels	O
.	O
We	O
observe	O
IL-4	B-protein
-dependent	O
redirection	O
of	O
phenotype	O
in	O
cells	O
that	O
have	O
already	O
committed	O
to	O
a	O
non-IL-4-producing	O
fate	O
,	O
inconsistent	O
with	O
predictions	O
of	O
the	O
selective	O
model	O
.	O
Further	O
,	O
retroviral	O
tagging	O
of	O
naive	O
progenitors	O
with	O
the	O
Th2-specific	B-protein
transcription	I-protein
factor	I-protein
GATA-3	I-protein
provided	O
direct	O
evidence	O
for	O
instructive	O
differentiation	O
,	O
and	O
no	O
evidence	O
for	O
the	O
selective	O
outgrowth	O
of	O
cells	O
committed	O
to	O
either	O
the	O
Th1	O
or	O
Th2	O
fate	O
.	O
These	O
data	O
would	O
seem	O
to	O
exclude	O
selection	O
as	O
an	O
exclusive	O
mechanism	O
in	O
Th1	O
/	O
Th2	O
differentiation	O
,	O
and	O
support	O
an	O
instructive	O
model	O
of	O
cytokine-driven	O
transcriptional	O
programming	O
of	O
cell	O
fate	O
decisions	O
.	O
In	O
vitro-activated	O
human	O
lupus	O
T	O
cells	O
express	O
normal	O
estrogen	B-protein
receptor	I-protein
proteins	I-protein
which	O
bind	O
to	O
the	O
estrogen	O
response	O
element	O
.	O
We	O
have	O
shown	O
that	O
estrogen	B-protein
receptor	I-protein
(	O
ERalpha	O
,	O
ERbeta	O
)	O
transcripts	O
are	O
expressed	O
in	O
SLE	O
and	O
normal	O
T	O
cells	O
.	O
In	O
this	O
study	O
,	O
T	O
cell	O
nuclear	O
extracts	O
from	O
female	O
lupus	O
patients	O
and	O
normal	O
donors	O
were	O
tested	O
for	O
biologically	O
active	O
ER	B-protein
proteins	O
capable	O
of	O
binding	O
to	O
the	O
human	O
estrogen	O
response	O
element	O
(	O
hERE	O
)	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O
When	O
peripheral	O
blood	O
T	O
cells	O
were	O
stimulated	O
with	O
17beta-estradiol	O
(	O
E2	O
)	O
,	O
PMA	O
and	O
ionomycin	O
,	O
two	O
major	O
retarded	O
bands	O
in	O
T	O
cell	O
nuclear	O
extracts	O
exhibited	O
a	O
migration	O
pattern	O
similar	O
to	O
slow	O
migrating	O
protein-ERE	B-protein
complexes	I-protein
in	O
human	O
breast	O
cancer	O
cell	O
extracts	O
.	O
T	O
cells	O
cultured	O
only	O
with	O
E2	O
did	O
not	O
have	O
these	O
complexes	O
.	O
The	O
formation	O
of	O
the	O
complexes	O
was	O
inhibited	O
by	O
competition	O
with	O
the	O
hERE	O
cold	O
oligonucleotide	O
and	O
partially	O
with	O
anti-ERalpha	B-protein
antibodies	I-protein
.	O
There	O
was	O
no	O
notable	O
difference	O
in	O
the	O
migration	O
pattern	O
of	O
ERE-binding	B-protein
proteins	I-protein
between	O
the	O
SLE	O
and	O
normal	O
T	O
cell	O
extracts	O
.	O
Together	O
,	O
these	O
results	O
suggest	O
that	O
activated	O
human	O
T	O
cells	O
,	O
whether	O
lupus-derived	O
or	O
normal-derived	O
,	O
contain	O
biologically	O
active	B-protein
ERalpha	I-protein
proteins	I-protein
.	O
Other	O
factors	O
may	O
be	O
responsible	O
for	O
differential	O
sensitivity	O
of	O
lupus	O
T	O
cells	O
to	O
estrogen	O
.	O
Mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitor	O
on	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
production	O
of	O
monocytes	O
.	O
If	O
the	O
inflammatory	O
response	O
becomes	O
excessive	O
or	O
uncontrolled	O
by	O
some	O
stimuli	O
,	O
inappropriate	O
inflammatory	O
responses	O
occur	O
.	O
Monocytes	O
are	O
extremely	O
important	O
cells	O
for	O
regulating	O
the	O
cytokine	O
network	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
)	O
and	O
interleukin-	O
(	O
IL	O
)	O
10	O
,	O
which	O
are	O
mainly	O
synthesized	O
by	O
monocytes	O
,	O
are	O
representative	B-protein
cytokines	I-protein
that	O
play	O
a	O
central	O
role	O
in	O
the	O
cytokine	O
network	O
.	O
Protease	O
inhibitors	O
such	O
as	O
gabexate	O
mesilate	O
(	O
GM	O
)	O
and	O
ulinastatin	O
(	O
UTI	O
)	O
have	O
been	O
shown	O
to	O
have	O
various	O
beneficial	O
effects	O
by	O
inhibiting	O
the	O
activation	O
of	O
leukocytes	O
,	O
but	O
the	O
mechanism	O
for	O
this	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
.	O
In	O
this	O
study	O
we	O
investigated	O
the	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
proinflammatory	O
cytokine	O
production	O
of	O
lipopolysaccharide-	O
(	O
LPS	O
)	O
stimulated	O
monocytes	O
.	O
LPS-stimulated	O
monocytes	O
were	O
treated	O
with	O
GM	O
or	O
UTI	B-protein
.	O
The	O
value	O
of	O
TNFalpha	B-protein
and	O
IL-10	B-protein
in	O
the	O
culture	O
medium	O
of	O
monocytes	O
was	O
measured	O
and	O
each	O
mRNA	O
expression	O
was	O
assayed	O
.	O
The	O
inhibitory	O
effect	O
of	O
protease	O
inhibitors	O
on	O
the	O
activity	O
of	O
intracellular	O
signal	O
transduction	O
pathways	O
such	O
as	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NFkappaB	O
)	O
were	O
also	O
evaluated	O
.	O
GM	O
decreased	O
the	O
TNFalpha	B-protein
production	O
of	O
LPS-stimulated	O
monocytes	O
as	O
shown	O
by	O
the	O
inhibition	O
of	O
mRNA	O
expression	O
and	O
increased	O
the	O
IL-10	O
production	O
of	O
LPS-stimulated	O
monocytes	O
.	O
GM	O
also	O
suppressed	O
the	O
NFkappaB	O
activity	O
of	O
LPS-stimulated	O
monocytes	O
.	O
UTI	O
decreased	O
the	O
TNFalpha	B-protein
production	O
of	O
LPS-stimulated	O
monocytes	O
,	O
but	O
did	O
not	O
inhibit	O
the	O
TNFalpha	O
mRNA	O
expression	O
.	O
The	O
present	O
study	O
shows	O
that	O
the	O
inhibitory	O
effect	O
of	O
GM	O
on	O
the	O
TNFalpha	B-protein
production	O
of	O
activated	O
human	O
monocytes	O
is	O
mediated	O
by	O
the	O
suppression	O
of	O
NFkappaB	O
activation	O
,	O
while	O
the	O
mechanism	O
of	O
UTI	O
inhibiting	O
TNFalpha	B-protein
production	O
of	O
human	O
monocytes	O
may	O
be	O
due	O
to	O
the	O
inhibition	O
of	O
either	O
the	O
translation	O
or	O
secretion	O
of	O
TNFalpha	B-protein
.	O
Homocysteine	B-protein
stimulates	O
the	O
expression	O
of	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
in	O
endothelial	O
cells	O
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O
Hyperhomocysteinemia	O
has	O
been	O
identified	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O
The	O
infiltration	O
of	O
monocytes	O
into	O
the	O
arterial	O
wall	O
is	O
one	O
of	O
the	O
key	O
events	O
during	O
atherogenesis	O
.	O
Monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
is	O
a	O
potent	O
chemokine	O
that	O
stimulates	O
the	O
migration	O
of	O
monocytes	O
into	O
the	O
intima	O
of	O
the	O
arterial	O
wall	O
.	O
The	O
mechanism	O
by	O
which	O
increased	O
monocyte	O
infiltration	O
occurs	O
in	O
atherosclerotic	O
lesions	O
in	O
patients	O
with	O
hyperhomocysteinemia	O
has	O
not	O
been	O
delineated	O
.	O
The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
homocysteine	O
on	O
MCP-1	B-protein
production	O
in	O
endothelial	O
cells	O
.	O
Cells	O
were	O
incubated	O
with	O
homocysteine	O
.	O
The	O
secretion	O
of	O
MCP-1	B-protein
protein	I-protein
was	O
significantly	O
increased	O
(	O
195	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
cells	O
treated	O
with	O
pathological	O
concentrations	O
of	O
homocysteine	O
.	O
Such	O
effect	O
was	O
accompanied	O
by	O
an	O
increased	O
expression	O
of	O
MCP-1	O
mRNA	O
(	O
176	O
%	O
as	O
compared	O
to	O
the	O
control	O
)	O
in	O
endothelial	O
cells	O
which	O
resulted	O
in	O
enhanced	O
monocyte	O
chemotaxis	O
.	O
The	O
p38	B-protein
MAP	I-protein
kinase	I-protein
as	O
well	O
as	O
other	O
members	O
of	O
the	O
p38	B-protein
MAP	I-protein
kinase	I-protein
pathway	O
,	O
including	O
MKK3	O
,	O
MKK6	O
,	O
ATF-2	O
and	O
Elk-1	O
,	O
were	O
activated	O
in	O
homocysteine-treated	O
cells	O
.	O
Homocysteine-induced	O
MCP-1	O
expression	O
and	O
subsequent	O
monocyte	O
chemotaxis	O
were	O
blocked	O
by	O
a	O
p38	O
MAP	O
kinase	O
inhibitor	O
(	O
SB203580	O
)	O
suggesting	O
that	O
the	O
p38	B-protein
MAP	I-protein
kinase	I-protein
pathway	O
might	O
be	O
involved	O
in	O
homocysteine-induced	O
MCP-1	O
expression	O
in	O
endothelial	O
cells	O
.	O
In	O
contrast	O
,	O
staurosporine	O
,	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
inhibitor	I-protein
,	O
had	O
no	O
effect	O
on	O
homocysteine-induced	O
MCP-1	O
expression	O
.	O
In	O
conclusion	O
,	O
our	O
results	O
indicate	O
that	O
homocysteine	O
stimulates	O
MCP-1	B-protein
expression	O
in	O
endothelial	O
cells	O
leading	O
to	O
enhanced	O
monocyte	O
chemotaxis	O
.	O
Inducible	O
resistance	O
to	O
Fas-mediated	O
apoptosis	O
in	O
B	O
cells	O
.	O
Apoptosis	O
produced	O
in	O
B	O
cells	O
through	O
Fas	O
(	O
APO-1	O
,	O
CD95	O
)	O
triggering	O
is	O
regulated	O
by	O
signals	O
derived	O
from	O
other	O
surface	B-protein
receptors	I-protein
:	O
CD40	B-protein
engagement	O
produces	O
upregulation	O
of	O
Fas	O
expression	O
and	O
marked	O
susceptibility	O
to	O
Fas	B-protein
-induced	O
cell	O
death	O
,	O
whereas	O
antigen	O
receptor	O
engagement	O
,	O
or	O
IL-4R	O
engagement	O
,	O
inhibits	O
Fas	B-protein
killing	O
and	O
in	O
so	O
doing	O
induces	O
a	O
state	O
of	O
Fas	O
-resistance	O
,	O
even	O
in	O
otherwise	O
sensitive	O
,	O
CD40	B-protein
-stimulated	O
targets	O
.	O
Surface	B-protein
immunoglobulin	I-protein
and	I-protein
IL-4R	I-protein
utilize	I-protein
at	O
least	O
partially	O
distinct	O
pathways	O
to	O
produce	O
Fas	O
-resistance	O
that	O
differentially	O
depend	O
on	O
PKC	B-protein
and	O
STAT6	B-protein
,	O
respectively	O
.	O
Further	O
,	O
surface	O
immunoglobulin	O
signaling	O
for	O
inducible	O
Fas	O
-resistance	O
bypasses	O
Btk	B-protein
,	O
requires	O
NF-kappaB	B-protein
,	O
and	O
entails	O
new	O
macromolecular	O
synthesis	O
.	O
Terminal	O
effectors	O
of	O
B	O
cell	O
Fas	O
-resistance	O
include	O
the	O
known	O
anti-apoptotic	O
gene	O
products	O
,	O
Bcl-xL	O
and	O
FLIP	O
,	O
and	O
a	O
novel	O
anti-apoptotic	O
gene	O
that	O
encodes	O
FAIM	O
(	O
Fas	O
Apoptosis	O
Inhibitory	B-protein
Molecule	I-protein
)	O
.	O
faim	O
was	O
identified	O
by	O
differential	O
display	O
and	O
exists	O
in	O
two	O
alternatively	O
spliced	O
forms	O
;	O
faim-S	O
is	O
broadly	O
expressed	O
,	O
but	O
faim-L	O
expression	O
is	O
tissue-specific	O
.	O
The	O
FAIM	O
sequence	O
is	O
highly	O
evolu-	O
tionarily	O
conserved	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
this	O
molecule	O
throughout	O
phylogeny	O
.	O
Inducible	O
resistance	O
to	O
Fas	O
killing	O
is	O
hypothesized	O
to	O
protect	O
foreign	O
antigen-specific	O
B	O
cells	O
during	O
potentially	O
hazardous	O
interactions	O
with	O
FasL-bearing	O
T	O
cells	O
,	O
whereas	O
autoreactive	O
B	O
cells	O
fail	O
to	O
become	O
Fas	B-protein
-resistant	O
and	O
are	O
deleted	O
via	O
Fas	B-protein
-dependent	O
cytotoxicity	O
.	O
Inadvertent	O
or	O
aberrant	O
acquisition	O
of	O
Fas	O
-resistance	O
may	O
permit	O
autoreactive	O
B	O
cells	O
to	O
escape	O
Fas	O
deletion	O
,	O
and	O
malignant	O
lymphocytes	O
to	O
impede	O
anti-tumor	O
immunity	O
.	O
Stromal	B-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
alpha	I-protein
-induced	O
chemotaxis	O
in	O
T	O
cells	O
is	O
mediated	O
by	O
nitric	O
oxide	O
signaling	O
pathways	O
.	O
Stromal	B-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
alpha	I-protein
(	O
SDF1	B-protein
alpha	I-protein
)	O
and	O
its	O
cognate	B-protein
chemokine	I-protein
receptor	I-protein
CXCR4	I-protein
act	O
as	O
potent	O
chemoattractants	O
and	O
regulate	O
trafficking	O
and	O
homing	O
of	O
hematopoietic	O
progenitor	O
cells	O
and	O
lymphocytes	O
.	O
However	O
,	O
the	O
molecular	O
mechanisms	O
regulating	O
SDF1	B-protein
alpha	I-protein
-driven	O
cell	O
migration	O
are	O
not	O
well	O
defined	O
.	O
In	O
this	O
study	O
,	O
we	O
have	O
explored	O
the	O
roles	O
of	O
the	O
second	O
messenger	O
NO	O
and	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
SDF1	B-protein
alpha	I-protein
-induced	O
T	O
cell	O
migration	O
.	O
SDF1	O
alpha	O
treatment	O
of	O
Jurkat	O
T	O
cells	O
increased	O
the	O
activity	O
of	O
NO	O
synthase	O
,	O
which	O
catalyzes	O
the	O
generation	O
of	O
NO	O
.	O
We	O
observed	O
that	O
pretreatment	O
of	O
Jurkat	O
cells	O
or	O
activated	O
PBLs	O
with	O
several	O
NO	O
donors	O
significantly	O
enhanced	O
the	O
SDF1	B-protein
alpha	I-protein
-induced	O
migration	O
,	O
whereas	O
various	O
inhibitors	O
of	O
NO	O
synthase	O
markedly	O
abrogated	O
the	O
chemotactic	O
response	O
in	O
a	O
concentration-dependent	O
manner	O
.	O
Furthermore	O
,	O
we	O
observed	O
that	O
inhibitors	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
,	O
which	O
is	O
linked	O
to	O
NO	O
signaling	O
pathways	O
,	O
also	O
significantly	O
blocked	O
the	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotactic	O
response	O
.	O
However	O
,	O
these	O
compounds	O
did	O
not	O
have	O
a	O
significant	O
effect	O
on	O
SDF1	B-protein
alpha	I-protein
-induced	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activity	O
.	O
In	O
addition	O
,	O
the	O
MAP/Erk	B-protein
kinase	I-protein
kinase	I-protein
inhibitor	I-protein
PD98059	I-protein
did	O
not	O
abrogate	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
.	O
AKT	O
,	O
which	O
has	O
been	O
shown	O
to	O
mediate	O
NO	O
production	O
,	O
was	O
also	O
phosphorylated	O
upon	O
SDF1	O
alpha	O
stimulation	O
.	O
These	O
studies	O
suggest	O
that	O
NO-related	O
signaling	O
pathways	O
may	O
mediate	O
SDF1	B-protein
alpha	I-protein
-induced	O
chemotaxis	O
,	O
but	O
not	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
activation	O
.	O
The	O
lack	O
of	O
NF-kappa	B-protein
B	I-protein
transactivation	I-protein
and	I-protein
PKC	I-protein
epsilon	O
expression	O
in	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocytes	O
correlates	O
with	O
negative	O
selection	O
.	O
Deletion	O
of	O
autoreactive	O
thymocytes	O
at	O
the	O
DP	O
stage	O
is	O
the	O
basis	O
for	O
tolerance	O
to	O
thymus-expressed	B-protein
self	I-protein
antigens	I-protein
.	O
In	O
this	O
study	O
we	O
investigated	O
whether	O
distinct	O
signalling	O
pathways	O
are	O
induced	O
in	O
DP	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
upon	O
stimulation	O
with	O
antigen	O
.	O
Using	O
triple	O
transgenic	O
mice	O
expressing	O
a	O
TCR	O
transgene	O
,	O
dominant	B-protein
negative	I-protein
ras/Mek	I-protein
proteins	I-protein
and	O
a	O
reporter	O
gene	O
construct	O
with	O
AP-1	B-protein
or	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
sites	I-protein
,	O
we	O
showed	O
a	O
complete	O
lack	O
of	O
transcriptional	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
but	O
not	O
AP-1	B-protein
in	O
DP	O
thymocytes	O
,	O
whereas	O
both	O
were	O
transcriptionally	O
active	O
in	O
mature	O
T	O
cells	O
after	O
antigenic	O
stimulation	O
.	O
Lack	O
of	O
NF-kappa	B-protein
B	I-protein
induction	O
correlated	O
with	O
increased	O
death	O
in	O
response	O
to	O
antigen	O
.	O
AP-1	O
induction	O
was	O
dependent	O
on	O
the	O
integrity	O
of	O
the	O
ras/Mek	O
pathway	O
indicating	O
that	O
this	O
pathway	O
was	O
activated	O
in	O
the	O
DP	O
thymocytes	O
.	O
In	O
contrast	O
,	O
we	O
found	O
a	O
complete	O
lack	O
of	O
constitutive	O
expression	O
of	O
the	O
epsilon	O
isoform	O
of	O
Protein	B-protein
Kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
in	O
DP	O
thymocytes	O
,	O
although	O
it	O
was	O
present	O
in	O
mature	O
thymocytes	O
and	O
peripheral	O
T	O
cells	O
.	O
Taken	O
together	O
the	O
results	O
suggest	O
that	O
the	O
lack	O
of	O
PKC	O
epsilon	O
in	O
DP	O
thymocytes	O
could	O
lead	O
to	O
the	O
absence	O
of	O
NF-kappa	B-protein
B	I-protein
activity	O
after	O
antigenic	O
stimulation	O
contributing	O
to	O
negative	O
selection	O
.	O
Cell	O
Death	O
and	O
Differentiation	O
(	O
2000	O
)	O
7	O
,	O
1253	O
-	O
1262	O
.	O
CD2	O
stimulation	O
leads	O
to	O
the	O
delayed	O
and	O
prolonged	O
activation	O
of	O
STAT1	B-protein
in	O
T	O
cells	O
but	O
not	O
NK	O
cells	O
.	O
OBJECTIVE	O
:	O
T	O
lymphocytes	O
can	O
be	O
activated	O
by	O
soluble	B-protein
factors	I-protein
such	O
as	O
cytokines	B-protein
or	O
through	O
direct	O
cell-cell	O
interactions	O
.	O
Although	O
cytokine	B-protein
receptors	I-protein
are	O
known	O
to	O
signal	O
through	O
STAT	B-protein
family	I-protein
transcription	I-protein
factors	I-protein
,	O
the	O
mechanisms	O
by	O
which	O
other	O
cell-surface	O
molecules	O
,	O
such	O
as	O
CD2	B-protein
,	O
transduce	O
signals	O
is	O
unclear	O
.	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
stimulation	O
of	O
T	O
cells	O
through	O
CD2	O
recapitulates	O
aspects	O
of	O
cytokine	B-protein
-induced	O
T-cell	O
activation	O
by	O
use	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
T	O
cells	O
were	O
treated	O
with	O
anti-CD2	B-protein
antibodies	I-protein
or	O
cells	O
bearing	O
the	O
natural	B-protein
CD2	I-protein
ligand	I-protein
CD58	I-protein
,	O
after	O
which	O
signaling	O
through	O
STAT	B-protein
transcription	I-protein
factors	I-protein
was	O
assessed	O
.	O
RESULTS	O
:	O
Stimulation	O
of	O
CD2	B-protein
on	O
primary	O
T	O
lymphocytes	O
leads	O
to	O
the	O
tyrosine	O
phosphorylation	O
,	O
nuclear	O
translocation	O
,	O
and	O
DNA	O
binding	O
of	O
STAT1	B-protein
.	O
In	O
contrast	O
to	O
stimulation	O
by	O
cytokines	B-protein
,	O
the	O
activation	O
of	O
STAT1	B-protein
in	O
response	O
to	O
CD2	O
ligation	O
is	O
delayed	O
and	O
does	O
not	O
involve	O
Jak	B-protein
kinases	I-protein
.	O
Furthermore	O
,	O
while	O
STAT	O
phosphorylation	O
induced	O
by	O
cytokines	B-protein
is	O
generally	O
transient	O
,	O
STAT1	B-protein
phosphorylation	O
following	O
CD2	O
stimulation	O
persists	O
for	O
a	O
period	O
of	O
days	O
.	O
Transcription	O
of	O
key	O
target	O
genes	O
such	O
as	O
IRF1	O
and	O
c-fos	O
proceeds	O
with	O
delayed	O
kinetics	O
following	O
CD2	O
stimulation	O
,	O
suggesting	O
that	O
this	O
unique	O
pattern	O
of	O
STAT	O
activation	O
may	O
lead	O
to	O
a	O
distinct	O
cellular	O
response	O
following	O
CD2	O
ligation	O
.	O
This	O
pathway	O
appears	O
to	O
be	O
restricted	O
to	O
T	O
cells	O
,	O
as	O
stimulation	O
of	O
CD2	B-protein
on	O
NK	O
cells	O
does	O
not	O
lead	O
to	O
STAT1	B-protein
activation	O
.	O
CONCLUSION	O
:	O
Stimulation	O
of	O
T	O
cells	O
through	O
cell-surface	O
molecules	O
such	O
as	O
CD2	O
involves	O
activation	O
of	O
STAT	B-protein
transcription	I-protein
factors	I-protein
,	O
thus	O
recapitulating	O
elements	O
of	O
cytokine	O
signaling	O
.	O
NFATc1	O
and	O
NFATc2	O
together	O
control	O
both	O
T	O
and	O
B	O
cell	O
activation	O
and	O
differentiation	O
.	O
NFAT	B-protein
transcription	I-protein
factors	I-protein
play	O
critical	O
roles	O
in	O
gene	O
transcription	O
during	O
immune	O
responses	O
.	O
To	O
investigate	O
further	O
the	O
two	O
most	O
prominent	O
NFAT	B-protein
family	I-protein
members	I-protein
,	O
NFATc1	O
and	O
NFATc2	O
,	O
we	O
generated	O
mice	O
bearing	O
lymphoid	O
systems	O
devoid	O
of	O
both	O
.	O
Doubly	O
deficient	O
T	O
cells	O
displayed	O
cell	O
surface	O
markers	O
of	O
activation	O
yet	O
were	O
significantly	O
deficient	O
in	O
the	O
development	O
of	O
multiple	O
effector	O
functions	O
,	O
including	O
Th	O
cytokine	O
production	O
,	O
surface	O
effector	O
molecule	O
expression	O
,	O
and	O
cytolytic	O
activity	O
.	O
Nevertheless	O
,	O
doubly	O
deficient	O
B	O
cells	O
were	O
hyperactivated	O
,	O
as	O
evidenced	O
by	O
extremely	O
elevated	O
serum	O
IgG1	O
and	O
IgE	O
,	O
as	O
well	O
as	O
plasma	O
cell	O
expansion	O
and	O
infiltration	O
of	O
end	O
organs	O
.	O
Thus	O
,	O
in	O
T	O
cells	O
,	O
NFATc1	O
and	O
NFATc2	O
are	O
dispensable	O
for	O
inflammatory	O
reactivity	O
but	O
are	O
required	O
for	O
effector	O
differentiation	O
,	O
while	O
in	O
B	O
cells	O
,	O
NFATs	O
regulate	O
both	O
normal	O
homeostasis	O
and	O
differentiation	O
.	O
Epstein-barr	O
virus	O
immediate-early	O
protein	O
BZLF1	O
is	O
SUMO-1	O
modified	O
and	O
disrupts	O
promyelocytic	O
leukemia	O
bodies	O
.	O
Although	O
the	O
immediate-early	B-protein
proteins	I-protein
of	O
both	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
are	O
known	O
to	O
modify	O
promyelocytic	O
leukemia	O
(	O
PML	O
)	O
(	O
ND10	O
)	O
bodies	O
in	O
the	O
nucleus	O
of	O
the	O
host	O
cell	O
,	O
it	O
has	O
been	O
unclear	O
whether	O
lytic	O
infection	O
with	O
gamma	O
herpesviruses	O
induces	O
a	O
similar	O
effect	O
.	O
The	O
PML	B-protein
protein	I-protein
is	O
induced	O
by	O
interferon	B-protein
,	O
involved	O
in	O
major	O
histocompatibility	O
complex	O
class	O
I	O
presentation	O
,	O
and	O
necessary	O
for	O
certain	O
types	O
of	O
apoptosis	O
.	O
Therefore	O
,	O
it	O
is	O
likely	O
that	O
PML	O
bodies	O
function	O
in	O
an	O
antiviral	O
capacity	O
.	O
SUMO-1	O
modification	O
of	O
PML	B-protein
is	O
known	O
to	O
be	O
required	O
for	O
the	O
formation	O
of	O
PML	O
bodies	O
.	O
To	O
examine	O
whether	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
replication	O
interferes	O
with	O
PML	O
bodies	O
,	O
we	O
expressed	O
the	O
EBV	O
immediate-early	O
genes	O
BZLF1	O
(	O
Z	O
)	O
and	O
BRLF1	O
(	O
R	O
)	O
in	O
EBV-positive	O
cell	O
lines	O
and	O
examined	O
PML	O
localization	O
.	O
Both	O
Z	O
and	O
R	O
expression	O
resulted	O
in	O
PML	O
dispersion	O
in	O
EBV-positive	O
cells	O
.	O
Z	O
but	O
not	O
R	O
expression	O
is	O
sufficient	O
to	O
disrupt	O
PML	O
bodies	O
in	O
EBV-negative	O
cell	O
lines	O
.	O
We	O
show	O
that	O
dispersion	O
of	O
PML	O
bodies	O
by	O
Z	O
requires	O
a	O
portion	O
of	O
the	O
transcriptional	B-protein
activation	I-protein
domain	I-protein
of	O
Z	B-protein
but	O
not	O
the	O
DNA-binding	O
function	O
.	O
As	O
was	O
previously	O
reported	O
for	O
the	O
HSV-1	O
ICP0	O
and	O
CMV	B-protein
IE1	I-protein
proteins	I-protein
,	O
Z	O
reduces	O
the	O
amount	O
of	O
SUMO-1-modified	O
PML	O
.	O
We	O
also	O
found	O
that	O
Z	O
itself	O
is	O
SUMO-1	O
modified	O
(	O
through	O
amino	B-protein
acid	I-protein
12	I-protein
)	O
and	O
that	O
Z	O
competes	O
with	O
PML	O
for	O
limiting	O
amounts	O
of	O
SUMO-1	O
.	O
These	O
results	O
suggest	O
that	O
disruption	O
of	O
PML	O
bodies	O
is	O
important	O
for	O
efficient	O
lytic	O
replication	O
of	O
EBV	O
.	O
Furthermore	O
,	O
Z	B-protein
may	O
potentially	O
alter	O
the	O
function	O
of	O
a	O
variety	O
of	O
cellular	B-protein
proteins	I-protein
by	O
inhibiting	O
SUMO-1	O
modification	O
Suppression	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
and	O
stimulation	O
of	O
inhibitor	O
kappaB	O
by	O
troglitazone	O
:	O
evidence	O
for	O
an	O
anti-inflammatory	O
effect	O
and	O
a	O
potential	O
antiatherosclerotic	O
effect	O
in	O
the	O
obese	O
.	O
To	O
elucidate	O
whether	O
troglitazone	O
exerts	O
an	O
antiinflammatory	O
effect	O
in	O
humans	O
,	O
in	O
vivo	O
,	O
we	O
investigated	O
the	O
suppression	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NFkappaB	O
)	O
in	O
mononuclear	O
cells	O
(	O
MNC	O
)	O
by	O
this	O
drug	O
.	O
We	O
measured	O
intranuclear	O
NFkappaB	O
,	O
total	O
cellular	O
NFkappaB	O
,	O
inhibitor	O
kappaB	O
(	O
IkappaB	O
)	O
alpha	O
,	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
,	O
and	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
(	O
a	O
key	O
component	O
protein	O
of	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
oxidase	O
)	O
in	O
MNC	O
.	O
Plasma	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
soluble	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
sICAM-1	O
)	O
,	O
monocyte	B-protein
chemoattractant	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
,	O
plasminogen	B-protein
activator	I-protein
inhibitor	I-protein
type	I-protein
1	I-protein
(	O
PAI-1	O
)	O
,	O
C-reactive	B-protein
protein	I-protein
(	O
CRP	O
)	O
,	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
(	I-protein
antiinflammatory	I-protein
cytokine	I-protein
)	O
concentrations	O
were	O
also	O
measured	O
as	O
mediators	O
of	O
inflammatory	O
activity	O
that	O
are	O
regulated	O
by	O
the	O
proinflammatory	B-protein
transcription	I-protein
factor	I-protein
NFkappaB	I-protein
.	O
Seven	O
nondiabetic	O
obese	O
patients	O
were	O
given	O
400	O
mg	O
troglitazone	O
daily	O
for	O
4	O
weeks	O
.	O
Blood	O
samples	O
were	O
collected	O
before	O
and	O
at	O
weekly	O
intervals	O
thereafter	O
.	O
MNC	O
were	O
separated	O
;	O
and	O
the	O
levels	O
of	O
intranuclear	O
NFkappaB	O
,	O
total	O
cellular	O
NFkappaB	O
,	O
IkappaBalpha	B-protein
,	O
and	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
and	O
ROS	O
generation	O
were	O
determined	O
.	O
Plasma	O
was	O
used	O
to	O
measure	O
insulin	O
glucose	O
,	O
TNFalpha	B-protein
,	O
sICAM	O
,	O
MCP-1	B-protein
,	O
PAI-1	O
,	O
CRP	O
,	O
and	O
IL-10	B-protein
.	O
Plasma	O
insulin	O
concentrations	O
fell	O
significantly	O
at	O
week	O
1	O
,	O
from	O
31.2	O
+/-	O
29.1	O
to	O
14.2	O
+/-	O
11.4	O
mU/L	O
(	O
P	O
<	O
0.01	O
)	O
and	O
remained	O
low	O
throughout	O
4	O
weeks	O
.	O
Plasma	O
glucose	O
concentrations	O
did	O
not	O
alter	O
significantly	O
.	O
There	O
was	O
a	O
fall	O
in	O
intranuclear	O
NFkappaB	O
,	O
total	O
cellular	O
NFkappaB	O
,	O
and	O
p47	B-protein
(	I-protein
phox	I-protein
)	I-protein
subunit	I-protein
,	O
with	O
an	O
increase	O
in	O
cellular	O
IkappaBalpha	O
at	O
week	O
2	O
,	O
which	O
persisted	O
until	O
week	O
4	O
.	O
There	O
was	O
a	O
parallel	O
fall	O
in	O
ROS	O
generation	O
by	O
MNC	O
at	O
week	O
1	O
;	O
this	O
progressed	O
and	O
persisted	O
until	O
week	O
4	O
(	O
P	O
<	O
0.001	O
)	O
.	O
Plasma	B-protein
TNF-alpha	I-protein
,	O
sICAM-1	O
,	O
MCP-1	B-protein
,	O
and	O
PAI-1	O
concentrations	O
fell	O
significantly	O
at	O
week	O
4	O
.	O
Plasma	O
IL-10	O
concentration	O
increased	O
significantly	O
,	O
whereas	O
plasma	O
CRP	O
concentrations	O
decreased	O
.	O
We	O
conclude	O
that	O
troglitazone	O
has	O
an	O
antiinflammatory	O
action	O
that	O
may	O
contribute	O
to	O
its	O
putative	O
antiatherosclerotic	O
effects	O
.	O
Tyrosine	O
phosphorylation-dependent	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O
Requirement	O
for	O
p56	B-protein
LCK	I-protein
and	I-protein
ZAP-70	I-protein
protein	I-protein
tyrosine	I-protein
kinases	I-protein
.	O
Phosphorylation	O
of	O
the	O
N-terminal	B-protein
domain	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
inhibitory	I-protein
subunits	I-protein
induces	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
.	O
Although	O
serine	O
phosphorylation	O
has	O
been	O
shown	O
to	O
induce	O
ubiquitination	O
and	O
subsequent	O
proteasome-mediated	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
,	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
that	O
lead	O
to	O
release	O
of	O
active	B-protein
NF-kappa	I-protein
B	I-protein
in	O
T	O
cells	O
as	O
a	O
consequence	O
of	O
tyrosine	O
phosphorylation	O
of	O
I	O
kappa	O
B-alpha	O
[	O
Imbert	O
,	O
V.	O
,	O
Rupec	O
,	O
R.A.	O
,	O
Livolsi	O
,	O
A.	O
,	O
Pahl	O
,	O
,	O
Traenckner	O
,	O
,	O
Mueller-Dieckmann	O
,	O
C.	O
,	O
Farahifar	O
,	O
D.	O
,	O
Rossi	O
,	O
B.	O
,	O
Auberger	O
,	O
P.	O
,	O
Baeuerle	O
,	O
P.	O
&	O
Peyron	O
,	O
(	O
1996	O
)	O
Cell	O
86	O
,	O
787	O
--	O
798	O
]	O
.	O
The	O
involvement	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
p56	I-protein
(	I-protein
lck	I-protein
)	I-protein
and	O
ZAP-70	B-protein
in	O
this	O
reaction	O
is	O
demonstrated	O
here	O
using	O
specific	O
pharmacological	O
inhibitors	O
and	O
Jurkat	O
mutants	O
unable	O
to	O
express	O
these	O
kinases	B-protein
.	O
Although	O
the	O
inhibitors	O
prevented	O
both	O
pervanadate-induced	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
on	O
Tyr42	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
observed	O
that	O
,	O
in	O
p56	O
(	O
lck	O
)	O
-deficient	O
Jurkat	O
mutants	O
,	O
NF-kappa	B-protein
B	I-protein
could	O
still	O
associate	O
with	O
I	O
kappa	O
B-alpha	O
despite	O
phosphorylation	O
on	O
Tyr42	O
.	O
Furthermore	O
,	O
the	O
SH2	B-protein
domain	I-protein
of	O
p56	B-protein
(	I-protein
lck	I-protein
)	I-protein
appeared	O
to	O
be	O
